As filed with the U.S. Securities and Exchange
Commission on May 14, 2014
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
ANI PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in
its Charter)
Delaware
|
|
58-2301143
|
(State or Other Jurisdiction of Incorporation)
|
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
210 Main Street West
Baudette, Minnesota 56623
(218) 634-3500
|
|
(Address, Including Zip Code and Telephone
Number, Including Area Code, of Registrant’s Principal Executive Offices)
Charlotte C. Arnold
Vice President, Finance and Chief Financial
Officer
ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette, Minnesota 56623
(218) 634-3500
(Name, address, including zip code, and
telephone number, including area code, of agent for service)
Copies to:
Paul A. Gajer, Esq.
Jeffrey A. Baumel, Esq.
Dentons US LLP
1221 Avenue of the Americas
New York, New York 10020
(212) 768-6700
Approximate date of commencement of proposed sale to public
:
From time to time or at one time after this registration statement becomes effective in light of market conditions and other factors.
If the only securities being registered on this Form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box.
¨
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities
Act"), other than securities offered only in connection with dividend or interest reinvestment plans, check the following
box.
x
If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.
¨
If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
¨
If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule 462(e) under the Securities Act, check the following box.
¨
If this Form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box.
¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated
filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
|
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
x
|
CALCULATION OF REGISTRATION FEE
Title Of Each Class Of Securities
To Be Registered
|
|
Amount To Be
Registered
|
|
|
Proposed Maximum
Offering
Price Per Unit
|
|
|
Proposed Maximum
Aggregate Offering
Price
|
|
|
Amount Of
Registration
Fee
|
|
Primary Offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Securities
|
|
|
(1)(2)
|
|
|
|
(1)(2)
|
|
|
|
(2)(3)
|
|
|
|
|
|
Preferred Stock, par value $.0001 per share
|
|
|
(1)(2)
|
|
|
|
(1)(2)
|
|
|
|
(2)(3)
|
|
|
|
|
|
Common Stock, par value $.0001 per share
|
|
|
(1)(2)
|
|
|
|
(1)(2)
|
|
|
|
(2)(3)
|
|
|
|
|
|
Warrants
|
|
|
(1)(2)
|
|
|
|
(1)(2)
|
|
|
|
(2)(3)
|
|
|
|
|
|
Total Primary Offering
|
|
$
|
250,000,000(3)
|
|
|
|
100%
|
|
|
$
|
250,000,000
|
|
|
$
|
32,200(4)
|
|
Secondary Offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, par value $.0001 per share
|
|
|
3,500,000(5)
|
|
|
$
|
30.60(6)
|
|
|
$
|
107,100,000
|
|
|
$
|
13,795
|
|
TOTAL
|
|
|
|
|
|
|
|
|
|
$
|
357,100,000
|
|
|
$
|
45,995
|
|
|
(1)
|
There are being registered under this registration statement
such indeterminate number of shares of common stock and preferred stock of the registrant, such indeterminate number of warrants
of the registrant and such indeterminate principal amount of debt securities of the registrant, as shall have an aggregate initial
offering price not to exceed $250,000,000. There are being registered under this registration statement such indeterminate number
of each identified class of the identified securities as may be issued upon conversion, exchange, or exercise of any other securities
that provide for such conversion, exchange or exercise, up to a proposed maximum offering price of $250,000,000. In addition,
pursuant to Rule 416 under the Securities Act, the shares of common stock and preferred stock being registered hereunder include
such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered
hereunder as a result of stock splits, stock dividends or similar transactions. The common stock to be issued pursuant to this
registration statement may include the issuance of shares of common stock issuable pursuant to currently outstanding warrants
as follows: (a) up to 6,667 shares issuable upon exercise of warrants at an exercise price of $90.00 per share through June 9,
2014; (b) up to 66,666 shares issuable upon exercise of warrants at an exercise price of $90.00 per share through August 12, 2014;
(c) up to 144,508 shares issuable upon exercise of warrants at an exercise price of $74.88 per share through September 8, 2015;
(d) up to 99,088 shares issuable upon exercise of warrants at an exercise price of $88.20 per share through June 23, 2015; (e)
up to 147,058 shares issuable upon exercise of warrants at an exercise price of $72.00 per share through December 30, 2015; and
(f) up to 63,333 shares issuable upon exercise of warrants at an exercise price of $9.00 per share through August 16, 2017. If
any debt securities are issued at an original issue discount, then the debt securities registered pursuant to this registration
statement shall include such greater principal amount as shall result in an amount to be registered hereunder that equals the
aggregate initial offering price, but in no event shall the initial public offering price of securities registered hereunder exceed
$250,000,000 less the aggregate dollar amount of all securities previously issued hereunder, or the equivalent thereof in one
or more foreign currencies. Any securities registered under this registration statement may be sold separately or as units with
other securities registered under this registration statement. The proposed maximum initial offering prices per unit will be determined,
from time to time, by the registrant in connection with the issuance by the registrant of the securities registered under this
registration statement.
|
|
(2)
|
Not specified with respect to each class of securities
being registered under this registration statement pursuant to General Instruction II.D. of Form S-3 under the Securities Act.
|
|
(3)
|
Estimated solely for the purpose of calculating the registration
fee in accordance with Rule 457(o) under the Securities Act. No additional consideration will be received for common stock, preferred
stock or debt securities that are issued upon conversion into or exchange for or exercise of preferred stock or debt securities.
The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in
connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of
security pursuant to General Instruction II.D of Form S-3 under the Securities Act.
|
|
(4)
|
Pursuant to Rule 457(o) under the Securities Act, the
registration fee is calculated on the maximum offering price of all securities listed, and the table does not specify information
by each class about the amount to be registered. Pursuant to Rule 415(a)(6) under the Securities Act, this registration statement
includes a total of $53,846,782 of unsold securities that had previously been registered under the Registrant’s registration
statement on Form S-3, initially filed with the U.S. Securities and Exchange Commission (the "SEC") on May 27, 2011
(No. 333-174597) (the "2011 Registration Statement"). The 2011 Registration Statement initially registered securities
for a maximum aggregate offering price of $150,000,000 and of that amount the Registrant has previously sold common stock and
warrants for an aggregate offering price of $96,153,218, leaving a balance of unsold securities with an aggregate offering price
of $53,846,782. The Registrant is paying herewith a registration fee of $25,265 in connection with the registration of $196,153,218
of newly registered securities. Pursuant to Rule 415(a)(6), the offering of the unsold securities registered under the 2011 Registration
Statement will be deemed terminated as of the date of effectiveness of this registration statement. If the Registrant sells any
of such unsold securities pursuant to the 2011 Registration Statement after the date of the initial filing, and prior to the date
of effectiveness, of this registration statement, the registrant will file a pre-effective amendment to this registration statement
which will reduce the number of such unsold securities included on this registration statement and increase the additional securities
registered hereon so that the total amount of securities registered hereon will equal $250,000,000, and will pay the additional
registration fee resulting therefrom.
|
|
(5)
|
Pursuant to Rule 416 under the Securities Act, the shares of Common Stock registered for resale are deemed to include an unspecified
number of additional shares of Common Stock to prevent dilution resulting from any further stock split, stock dividend or similar
transaction.
|
|
(6)
|
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the Securities Act
to be equal to $30.60 per share, the average of the high and low prices of the Common Stock as reported on The NASDAQ Global Market
on May 13, 2014.
|
The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant
to said Section 8(a), may determine.
The information in this prospectus is not complete
and may be changed. The Registrant may not sell these securities until the registration statement filed with the Securities and
Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to
buy these securities in any state where an offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED
MAY 14, 2014
PROSPECTUS
$250,000,000
ANI Pharmaceuticals, Inc.
Debt Securities, Preferred Stock, Common
Stock,
Debt Warrants and Equity Warrants
and
3,500,000 Shares
of
Common Stock
Offered for Resale by Selling Stockholders
The Company may sell from time to time
in one or more offerings up to $250,000,000 in the aggregate of:
|
·
|
the Company's secured or unsecured debt securities, in one or more series, which may be either senior, senior subordinated
or subordinated debt securities;
|
|
·
|
shares of the Company's preferred stock in one or more series;
|
|
·
|
shares of the Company's common stock;
|
|
·
|
any combination of the foregoing.
|
In addition, the selling stockholders to
be named in prospectus supplement may offer and sell, from time to time, up to 3,500,000 shares of the Company's common stock,
par value $.0001 per share. The selling stockholders may offer the shares of common stock from time to time through public or private
transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The
Company will not receive any of the proceeds from the sale of shares of the Company's common stock by the selling stockholders.
Neither the Company nor the selling stockholders are required to sell any securities.
When the Company decides to sell particular
securities or when the selling stockholders decide to sell shares of common stock, the Company will provide you with the specific
terms and the offering price of the securities the Company or the selling stockholders, as applicable, are then offering in one
or more prospectus supplements to this prospectus. The prospectus supplement may add to, change or update information contained
in this prospectus. The prospectus supplement may also contain important information about U.S. federal income tax consequences.
You should carefully read this prospectus, together with any prospectus supplements and information incorporated by reference in
this prospectus and any prospectus supplements, before you decide to invest.
This prospectus may not be used to
offer or sell any securities unless accompanied by a prospectus supplement.
The Company's common stock is quoted on
The NASDAQ Global Market under the trading symbol "ANIP."
Any common stock sold pursuant to this prospectus
or any prospectus supplement will be listed on that exchange, subject to official notice of issuance. Each prospectus supplement
to this prospectus will contain information, where applicable, as to any other listing on any national securities exchange of the
securities covered by the prospectus supplement.
The aggregate market value of the Company's
outstanding common stock held by non-affiliates is $237,796,811 based on 11,282,982 shares of outstanding common stock, of which
7,636,378 are held by non-affiliates, and a per share price of $31.14 based on the closing sale price of the Company's common stock
on May 7, 2014.
Investing in the Company's securities
involves significant risks. See "Risk Factors" beginning on page 5.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is May 14, 2014.
TABLE OF CONTENTS
This prospectus is part of a registration
statement the Company filed with the Securities and Exchange Commission. You should rely only on the information the Company has
provided or incorporated by reference in this prospectus or any prospectus supplement. Neither the Company nor the selling stockholders
have authorized anyone to provide you with additional or different information. The Company and the selling stockholders are not
making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in
this prospectus is accurate as of any date other than the date on the front of the prospectus.
ABOUT THIS PROSPECTUS
This prospectus is part of a registration
statement that the Company filed with the U.S. Securities and Exchange Commission (the "SEC") utilizing a "shelf"
registration process or continuous offering process, which allows the Company to offer and sell any combination of the securities
described in this prospectus in one or more offerings. Using this prospectus, the Company may offer up to a total dollar amount
of $250,000,000 of these securities. In addition, the selling stockholders to be identified in a prospectus supplement may from
time to time sell up to 3,500,000 shares of the Company's common stock in one or more offerings.
This prospectus provides you with a general
description of the securities the Company or selling stockholders may offer. Each time the Company or selling stockholders sell
securities pursuant to this registration statement and the prospectus contained herein, the Company will provide a prospectus supplement
that will contain specific information about the terms of that offering. That prospectus supplement may include additional risk
factors about the Company and the terms of that particular offering. Prospectus supplements may also add to, update or change the
information contained in this prospectus. To the extent that any statement that the Company makes in a prospectus supplement is
inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded
by those made in such prospectus supplement. In addition, as described in the section entitled "Where You Can Find More Information,"
the Company has filed and plans to continue to file other documents with the SEC that contain information about the Company and
the business conducted by the Company and its subsidiaries. Before you decide whether to invest in any of these securities, you
should read this prospectus, the prospectus supplement that further describes the offering of these securities and the information
the Company files with the SEC.
In this prospectus and any prospectus supplement,
unless otherwise indicated, the terms "ANI" and "the Company" refer and relate to ANI Pharmaceuticals, Inc.,
and its consolidated subsidiary.
ABOUT THE COMPANY
The Company's Business
ANI
Pharmaceuticals,
Inc. and its consolidated subsidiary, ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. ("ANIP" or "Subsidiary"),
is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.
The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids,
and complex formulations involving extended release and combination products. The Company has two pharmaceutical manufacturing
facilities located in Baudette, Minnesota, which are capable of producing oral solid dose products, as well as liquids and topicals,
narcotics, and potent products that must be manufactured in a fully-contained environment. The Company's strategy is to continue
to use these manufacturing assets to develop, produce, and distribute niche generic pharmaceutical products.
On June 19,
2013, pursuant to a merger agreement dated as of April 12, 2013, ANIP became a wholly-owned subsidiary of BioSante
Pharmaceuticals
,
Inc. ("BioSante") in an all-stock, tax-free reorganization (the "Merger"). The Merger was accounted for as
a reverse acquisition, pursuant to which ANIP was considered the acquiring entity for accounting purposes. BioSante was a publicly-held
pharmaceutical company focused on developing high value, medically-needed products. ANIP entered into the Merger to secure additional
capital and gain access to capital market opportunities as a public company.
In addition,
in
July
2013, the Company's stockholders approved and the Company subsequently effected (i)
a one-for-six reverse stock split of the
Company's
common stock and class C special stock,
with a proportional reduction in the number of authorized shares of its common stock, class C special stock and blank check preferred
stock, and (ii) a change of the Company's name from "BioSante Pharmaceuticals, Inc." to "ANI Pharmaceuticals, Inc."
Products, Markets and Contract Manufacturing
Products
The
Company's
established
product portfolio consists of both branded and generic pharmaceuticals,
including:
Generic Products
|
|
Branded Products
|
Esterified Estrogen with Methyltestosterone Tablets
|
|
Cortenema
®
|
Fluvoxamine Maleate Tablets
|
|
Reglan
®
Tablets
|
Hydrocortisone Enema
|
|
|
Metoclopramide Syrup
Opium Tincture
|
|
|
Esterified
Estrogen
with Methyltestosterone ("EEMT") is used to treat moderate to severe vasomotor
symptoms of menopause, such as hot flashes and heart
palpations
that are not improved by estrogen
medications alone. For the year ended December 31, 2013, EEMT comprised 33% of the Company’s net sales, a substantial increase
over the prior year wherein EEMT comprised only 9% of the Company’s net sales. In the third quarter of 2013, a significant
competitor stopped producing EEMT, which led to a material increase in the Company’s market share for the product and enabled
the Company to significantly increase the price it charges for the product.
Fluvoxamine
Maleate
is used to treat obsessions and compulsions in patients with obsessive-compulsive
disorder. It is generally used when the obsessions and compulsions in a patient interfere with the patient’s ability to function
socially and occupationally.
Hydrocortisone Enema and its branded equivalent,
Cortenema
®
are used for the treatment of ulcerative colitis, especially distal forms,
including
ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. The products have also proved useful in
some cases involving the transverse and ascending colons.
Metoclopramide syrup and its branded equivalent,
Reglan
®
, in tablet form, are prescribed for periods of four to twelve weeks for heartburn symptoms with gastroesophageal
reflux disease when certain other treatments do not work. The products relieve daytime heartburn and heartburn after meals and
also help ulcers in the esophagus to heal. The products also relieve symptoms of slow stomach emptying in people with diabetes
and help treat symptoms such as nausea, vomiting, heartburn, feeling full long after a meal, and loss of appetite.
Opium Tincture is used is to treat severe
diarrhea by slowing the movement of the intestines and decreasing the number and frequency of bowel movements.
Markets
In determining which products to pursue
for development, the Company targets markets whose products are complex to manufacture and therefore have higher barriers to entry.
These market factors provide opportunities for the Company's growth consistent with its competitive strengths at the same time
that they decrease the number of potential competitors in the markets. These markets currently include hormone and steroidal drugs,
oncolytics, and narcotics and complex formulations, including extended release and combination products.
Hormone and Steroidal Drugs
The market for hormone and steroidal drugs
includes hormone therapy to alleviate menopausal symptoms in women, contraceptives, testosterone replacement therapies for men,
and therapies for treating hormone-sensitive and other cancers.
Hormone Therapy ("HT") has been
an accepted medical treatment for alleviating the symptoms of menopause since the 1930s, with formal U.S. Food and Drug Administration
(the "FDA") approval for that use granted in 1942. Initially, HT consisted of estrogen only, but has evolved to include
combination therapies of estrogen, progesterone and androgens. The Company targets niche products in the HT and steroidal products
market for several reasons, including:
|
·
|
hormone and steroid products are a core competency based
on the Company’s manufacturing and product development teams' long history of manufacturing these types of products; and
|
|
·
|
the aging baby boom population, of which women represent
a majority, is expected to support continued growth in the HT market.
|
Oncolytics
The Company is positioned to develop and
manufacture niche oncolytic (anti-cancer) drugs due to the capabilities of the Company's containment facility and its expertise
in manufacturing segregation. In particular, the Company is targeting products subject to priority review by the FDA – those
with no blocking patents and no generic competition. In addition to one such product already under development, the Company has
identified additional priority review opportunities in oncolytics.
Narcotics
The Company's main manufacturing facility
in Baudette, Minnesota is licensed by the Drug Enforcement Administration for the manufacture and distribution of Schedule II
narcotics, i.e., drugs considered to have a high abuse risk but that also have safe and accepted medical uses in the United
States. In addition to its existing pipeline of four Abbreviated New Drug Applications, the Company has identified additional product
development opportunities in this market.
Contract Manufacturing
The Company manufactures pharmaceutical
products for several branded and generic companies, which outsource production to the Company in order to:
|
·
|
free-up internal resources to focus on sales and marketing
as well as research and development;
|
|
·
|
employ internal capacity to manufacture higher volume
or more critical products; and
|
|
·
|
utilize the Company’s specialized equipment
and expertise.
|
The Company considers contract manufacturing
to be an important component of its ongoing business. Given its highly specialized manufacturing capabilities, the Company is focused
on attracting niche contract manufacturing opportunities that fill idle capacity and offer high margins.
Trademark Notice
Cortenema®
and
Reglan® are
registered
trademarks of ANI
Pharmaceuticals
,
Inc. (
Baudette, Minnesota
).
Corporate Information
The Company’s principal executive
offices are located at 210 Main Street West, Baudette, Minnesota, 56623, its telephone number is (218) 634-3500, and its website
address is www.anipharmaceuticals.com. The website and the information contained therein or connected thereto are not incorporated
into this prospectus. The Company’s common stock is listed on The NASDAQ Global Market under the symbol "ANIP."
RISK FACTORS
Before
you
invest
in any of the Company's securities, in addition to the
other information in this prospectus and the applicable prospectus supplement, you
should
carefully consider the
risk
factors under the heading "Risk
Factors" contained in Part I, Item 1A in the Company's most recent Annual Report on Form 10-K and any risk
factors disclosed under the heading "Risk Factors" in Part II, Item 1A in any Quarterly Report on Form 10-Q
that the Company files after its most recent Annual Report on Form 10-K, which are incorporated by reference into this
prospectus
and the applicable prospectus supplement, as the same may be updated from time to time by the Company's future filings under the
Exchange Act.
The risks and uncertainties the Company
describes are not the only ones facing the Company. Additional risks and uncertainties not presently known to the Company or that
the Company currently deems immaterial may also impair its business or operations. Any adverse effect on the Company's business,
financial condition or operating results could result in a decline in the value of the securities and the loss of all or part of
your investment. The prospectus supplement applicable to each series of securities the Company or the selling stockholders offer
may contain a discussion of additional risks applicable to an investment in the Company and the securities the Company or the selling
stockholders are offering under that prospectus supplement.
FORWARD-LOOKING STATEMENTS
This prospectus and certain information
incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act").
Such statements include, but are not limited to, statements about the potential benefits of the recent Merger, the Company’s
plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position,
operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects," "plans," "potential,"
"future," "believes," "intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees,
subject to change. You should not place undue reliance on those statements because they are subject to numerous uncertainties,
risks and other factors relating to the Company’s operations and business environment and other factors, all of which are
difficult to predict and many of which are beyond the Company’s control.
Uncertainties and risks may cause
the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements.
Uncertainties and risks include, but are not limited to, the risk that the Company may in the future face increased difficulty
in importing raw materials and/or increased competition, for its Esterified Estrogen with Methyltestosterone Tablet product; competitive
conditions for the Company's other products may intensify; the Company may be required to seek the approval of the FDA for its
unapproved products or withdraw such products from the market; general business and economic conditions; the Company’s expectations
regarding trends in markets for the Company’s current and planned products; the Company’s future cash flow and its
ability to support its operations; the Company’s ability to obtain additional financing as needed; the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance of such products; and the marketing
success of the Company’s licensees or sublicensees.
More detailed information on these
and additional factors that could affect the Company’s actual results are described in the "Risk Factors" section
in Part I, Item 1A. of the Company's most recent annual report on Form 10-K and in other cautionary statements and risks included
in other reports the Company files with the SEC. All forward-looking statements in this prospectus speak only as of the date made
and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update
or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
USE OF PROCEEDS
Unless otherwise indicated in the prospectus
supplement, the Company will use the net proceeds from the sale of securities offered by this prospectus primarily to research,
develop, commercialize and expand its drug products; to acquire complementary businesses and technologies; and for other working
capital and general corporate purposes. As of the date of this prospectus supplement, the Company has not identified any specific
material proposed uses of the anticipated proceeds.
The amounts and timing of any expenditures
will vary depending on: the type, number, costs, and results of the product candidate development programs which the Company is
pursuing or may choose to pursue in the future; the scope, progress, expansion, costs, and results of its clinical trials; competitive
and technological developments; and the rate of growth, if any, of its business. Accordingly, unless otherwise indicated in the
prospectus supplement, the Company's management will have significant flexibility in applying the net proceeds of the offerings,
and investors will be relying on the judgment of the Company's management regarding the application of these net proceeds. Pending
the application of the net proceeds, the Company intends to invest the proceeds in short-term, interest-bearing instruments or
other investment-grade securities.
The Company will not receive any of the
proceeds from the sale of the Company's common stock by the selling stockholders.
DESCRIPTION OF DEBT
SECURITIES
The following description, together with
the additional information the Company includes in any applicable prospectus supplements, summarizes the material terms and provisions
of the debt securities that the Company may offer under this prospectus. While the terms the Company has summarized below will
apply generally to any future debt securities the Company may offer under this prospectus, the Company will describe the particular
terms of any debt securities that the Company may offer in more detail in the applicable prospectus supplement. The terms of any
debt securities the Company offers under a prospectus supplement may differ from the terms described below. However, no prospectus
supplement shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered
and described in this prospectus at the time of its effectiveness. As of December 31, 2013, the Company had no outstanding indebtedness,
including accrued interest.
The Company will issue the senior debt
securities under the senior indenture that the Company will enter into with the trustee named in the senior indenture. The Company
will issue the subordinated debt securities under the subordinated indenture that the Company will enter into with the trustee
named in the subordinated indenture. The Company has filed forms of these documents as exhibits to the registration statement which
includes this prospectus. The Company uses the term "indentures" in this prospectus to refer to both the senior indenture
and the subordinated indenture.
The indentures will be qualified under
the Trust Indenture Act of 1939. The Company uses the term "trustee" to refer to either the senior trustee or the subordinated
trustee, as applicable.
The following summaries of material provisions
of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety
by reference to, all the provisions of the indenture applicable to a particular series of debt securities. Except as the Company
may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.
General
Debt securities may be issued in separate
series without limitation as to aggregate principal amount. The Company may specify a maximum
aggregate
principal amount for the debt securities of any series.
The Company is not limited as to the amount
of debt securities it may issue under the indentures. The prospectus supplement will set forth:
|
·
|
whether the debt securities will be senior or subordinated;
|
|
·
|
any limit on the aggregate principal amount;
|
|
·
|
the person who shall be entitled to receive interest, if other than the record holder on the record date;
|
|
·
|
the date the principal will be payable;
|
|
·
|
the interest rate, if any, the date interest will accrue, the interest payment dates and the regular record dates;
|
|
·
|
the place where payments may be made;
|
|
·
|
any mandatory or optional redemption provisions;
|
|
·
|
if applicable, the method for determining how the principal, premium, if any, or interest will be calculated by reference to
an index or formula;
|
|
·
|
if other than U.S. currency, the currency or currency units in which principal, premium, if any, or interest will be payable
and whether the Company or the holder may elect payment to be made in a different currency;
|
|
·
|
the portion of the principal amount that will be payable upon acceleration of stated maturity, if other than the entire principal
amount;
|
|
·
|
if the principal amount payable at stated maturity will not be determinable as of any date prior to stated maturity, the amount
which will be deemed to be the principal amount;
|
|
·
|
any defeasance provisions if different from those described below under "Satisfaction and Discharge; Defeasance;"
|
|
·
|
any conversion or exchange provisions;
|
|
·
|
any obligation to redeem or purchase the debt securities pursuant to a sinking fund;
|
|
·
|
whether the debt securities will be issuable in the form of a global security;
|
|
·
|
any subordination provisions, if different from those described below under "Subordinated Debt Securities;"
|
|
·
|
any deletions of, or changes or additions to, the events of default or covenants; and
|
|
·
|
any other specific terms of such debt securities.
|
Unless otherwise specified in the prospectus
supplement:
|
·
|
the debt securities will be registered debt securities; and
|
|
·
|
registered debt securities denominated in U.S. dollars will be issued in denominations of $1,000 or an integral multiple of
$1,000.
|
Debt securities may be sold at a substantial
discount below their stated principal amount, bearing no interest or interest at a rate which at the time of issuance is below
market rates.
Exchange and Transfer
Debt securities may be transferred or exchanged
at the office of the security registrar or at the office of any transfer agent designated by the Company.
The Company will not impose a service charge
for any transfer or exchange, but the Company may require holders to pay any tax or other governmental charges associated with
any transfer or exchange.
In the event of any potential redemption
of debt securities of any series, the Company will not be required to:
|
·
|
issue, register the transfer of, or exchange, any debt security of that series during a period beginning at the opening of
business 15 days before the day of mailing of a notice of redemption and ending at the close of business on the day of the mailing;
or
|
|
·
|
register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except
the unredeemed portion being redeemed in part.
|
The Company may initially appoint the trustee
as the security registrar. Any transfer agent, in addition to the security registrar, initially designated by the Company will
be named in the prospectus supplement. The Company may designate additional transfer agents or change transfer agents or change
the office of the transfer agent. However, the Company will be required to maintain a transfer agent in each place of payment for
the debt securities of each series.
Global Securities
The debt securities of any series may be
represented, in whole or in part, by one or more global securities. Each global security will:
|
·
|
be registered in the name of a depositary that the Company will identify in a prospectus supplement;
|
|
·
|
be deposited with the depositary or nominee or custodian; and
|
|
·
|
bear any required legends.
|
No global security may be exchanged in
whole or in part for debt securities registered in the name of any person other than the depositary or any nominee unless:
|
·
|
the depositary has notified the Company that it is unwilling or unable to continue as depositary or has ceased to be qualified
to act as depositary;
|
|
·
|
an event of default is continuing; or
|
|
·
|
any other circumstances described in a prospectus supplement.
|
As long as the depositary, or its nominee,
is the registered owner of a global security, the depositary or nominee will be considered the sole owner and holder of the debt
securities represented by the global security for all purposes under the indenture. Except in the above limited circumstances,
owners of beneficial interests in a global security:
|
·
|
will not be entitled to have the debt securities registered in their names,
|
|
·
|
will not be entitled to physical delivery of certificated debt securities, and
|
|
·
|
will not be considered to be holders of those debt securities under the indentures.
|
Payments on a global security will be made
to the depositary or its nominee as the holder of the global security. Some jurisdictions have laws that require that certain purchasers
of securities take physical delivery of such securities in definitive form. These laws may impair the ability to transfer beneficial
interests in a global security.
Institutions that have accounts with the
depositary or its nominee are referred to as "participants." Ownership of beneficial interests in a global security will
be limited to participants and to persons that may hold beneficial interests through participants. The depositary will credit,
on its book-entry registration and transfer system, the respective principal amounts of debt securities represented by the global
security to the accounts of its participants.
Ownership of beneficial interests in a
global security will be shown on and effected through records maintained by the depositary, with respect to participants’
interests, or any participant, with respect to interests of persons held by participants on their behalf.
Payments, transfers and exchanges relating
to beneficial interests in a global security will be subject to policies and procedures of the depositary.
The depositary policies and procedures
may change from time to time. Neither the Company nor the trustee will have any responsibility or liability for the depositary’s
or any participant’s records with respect to beneficial interests in a global security.
Payment and Paying Agent
The provisions of this paragraph will apply
to debt securities unless otherwise indicated in the prospectus supplement. Payment of interest on a debt security on any interest
payment date will be made to the person in whose name the debt security is registered at the close of business on the regular record
date. Payment on debt securities of a particular series will be payable at the office of a paying agent or paying agents designated
by the Company. However, at the Company's option, the Company may pay interest by mailing a check to the record holder. The corporate
trust office initially will be designated as the Company's sole paying agent.
The Company may also name any other paying
agents in the prospectus supplement. The Company may designate additional paying agents, change paying agents or change the office
of any paying agent. However, the Company will be required to maintain a paying agent in each place of payment for the debt securities
of a particular series.
All moneys paid by the Company to a paying
agent for payment on any debt security which remain unclaimed at the end of two years after such payment was due will be repaid
to the Company. Thereafter, the holder may look only to the Company for such payment.
Consolidation, Merger and Sale of Assets
The Company may not consolidate with or
merge into any other person, in a transaction in which it is not the surviving corporation, or convey, transfer or lease the Company's
properties and assets substantially as an entirety to, any person, unless:
|
·
|
the successor, if any, is a U.S. corporation, limited liability company, partnership, trust or other entity;
|
|
·
|
the successor assumes the Company's obligations on the debt securities and under the indenture;
|
|
·
|
immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and
|
|
·
|
certain other conditions are met.
|
If the debt securities are convertible
for the Company's other securities or securities of other entities, the person with whom the Company consolidates or merges or
to whom the Company sells all of its property must make provisions for the conversion of the debt securities into securities which
the holders of the debt securities would have received if they had converted the debt securities before the consolidation, merger
or sale.
Events of Default
Unless the Company informs you otherwise
in the prospectus supplement, the indenture will define an event of default with respect to any series of debt securities as one
or more of the following events:
(1) failure to pay principal of or any premium on
any debt security of that series when due and payable;
(2) failure to pay any interest on any debt security
of that series when it becomes due and payable, and continuation of that failure for a period of 90 days (unless the entire amount
of such payment is deposited by the Company with the trustee or paying agent prior to the expiration of the 90-day period);
(3) failure to deposit any sinking fund payment, when
and as due in respect of any debt security of that series;
(4) failure to perform or breach of any other covenant
or warranty by the Company in the indenture (other than a covenant or warranty that has been included in the indenture solely for
the benefit of a series of debt securities other than the series), which failure continues uncured for a period of 90 days after
the Company receives the notice required in the indenture;
(5) the Company's bankruptcy, insolvency or reorganization;
and
(6) any other event of default with respect to debt
securities of that series that is described in the applicable prospectus supplement accompanying this prospectus.
An event of default of one series
of debt securities is not necessarily an event of default for any other series of debt securities.
If an event of default, other than an event
of default described in clause (5) above, shall occur and be continuing, either the trustee or the holders of at least 25% in aggregate
principal amount of the outstanding securities of that series may declare the principal amount of the debt securities of that series
to be due and payable immediately.
If an event of default described in clause
(5) above shall occur, the principal amount of all the debt securities of that series will automatically become immediately due
and payable. Any payment by the Company on the subordinated debt securities following any such acceleration will be subject to
the subordination provisions described below under "Subordinated Debt Securities."
After acceleration the holders of a majority
in aggregate principal amount of the outstanding securities of that series may, under certain circumstances, rescind and annul
such acceleration if all events of default, other than the non-payment of accelerated principal, or other specified amount, have
been cured or waived.
Other than the duty to act with the required
care during an event of default, the trustee will not be obligated to exercise any of its rights or powers at the request of the
holders unless the holders shall have offered to the trustee security and indemnity satisfactory to it against the costs, expenses
and liabilities to be incurred in compliance with such request.
Generally, the holders of a majority in
aggregate principal amount of the outstanding debt securities of any series will have the right to direct the time, method and
place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee.
A holder will not have any right to institute
any proceeding under the indentures, or for the appointment of a receiver or a trustee, or for any other remedy under the indentures,
unless:
(1) the holder has previously given to the trustee
written notice of a continuing event of default with respect to the debt securities of that series;
(2) the holders of at least 25% in aggregate principal
amount of the outstanding debt securities of that series have made a written request and have offered reasonable indemnity to the
trustee to institute the proceeding; and
(3) the trustee has failed to institute the proceeding
and has not received direction inconsistent with the original request from the holders of a majority in aggregate principal amount
of the outstanding debt securities of that series within 90 days after the original request.
A holder may not use the indenture to prejudice
the rights of any holder, or to obtain or to seek to obtain priority or preference over another holder or to enforce any right
under the indenture, except in the manner provided in the indenture and for the equal and ratable benefit of all holders (it being
understood that the trustee does not have an affirmative duty to ascertain whether or not such actions or forbearances are unduly
prejudicial to such holders).
Holders may, however, sue to enforce the
payment of principal, premium or interest on any debt security on or after the due date or to enforce the right, if any, to convert
any debt security without following the procedures listed in (1) through (3) above.
The Company will furnish the trustee an
annual statement by its officers as to whether or not the Company is in default in the performance of the indenture and, if so,
specifying all known defaults.
Modification and Waiver
The Company and the trustee may make modifications
and amendments to the indentures with the consent of the holders of a majority in aggregate principal amount of the outstanding
securities of each series affected by the modification or amendment.
However, neither the Company nor the trustee
may make any modification or amendment without the consent of the holder of each outstanding security of that series affected by
the modification or amendment if such modification or amendment would:
|
·
|
change the stated maturity of any debt security;
|
|
·
|
reduce the principal, premium, if any, or interest on any debt security;
|
|
·
|
reduce the principal of an original issue discount security or any other debt security payable on acceleration of maturity;
|
|
·
|
reduce the rate of interest on any debt security;
|
|
·
|
change the currency in which any debt security is payable;
|
|
·
|
impair the right to enforce any payment after the stated maturity or redemption date;
|
|
·
|
waive any default or event of default in payment of the principal of, premium or interest on any debt security;
|
|
·
|
waive a redemption payment or modify any of the redemption provisions of any debt security;
|
|
·
|
adversely affect the right to convert any debt security in any material respect; or
|
|
·
|
change the provisions in the indenture that relate to modifying or amending the indenture.
|
Satisfaction and Discharge; Defeasance
The Company may be discharged from its
obligations on the debt securities of any series that have matured or will mature or be redeemed within one year if the Company
deposits with the trustee enough cash to pay all the principal, interest and any premium due to the stated maturity date or redemption
date of the debt securities.
Each indenture will contain a provision
that permits the Company to elect:
|
·
|
to be discharged from all of the Company's obligations, subject to limited exceptions, with respect to any series of debt securities
then outstanding; and/or
|
|
·
|
to be released from the Company's obligations under the following covenants and from the consequences of an event of default
resulting from a breach of these covenants: (1) the subordination provisions under a subordinated indenture; and (2) covenants
as to payment of taxes and maintenance of corporate existence.
|
To make either of the above elections,
the Company must deposit in trust with the trustee enough money to pay in full the principal, interest and premium on the debt
securities. This amount may be made in cash and/or U.S. government obligations. As a condition to either of the above elections,
the Company must deliver to the trustee an opinion of counsel that the holders of the debt securities will not recognize income,
gain or loss for Federal income tax purposes as a result of the action.
If any of the above events occurs, the
holders of the debt securities of the series will not be entitled to the benefits of the indenture, except for the rights of holders
to receive payments on debt securities or the registration of transfer and exchange of debt securities and replacement of lost,
stolen or mutilated debt securities.
Notices
Notices to holders will be given by mail
to the addresses of the holders in the security register.
Governing Law
The indentures and the debt securities
will be governed by, and construed under, the law of the State of New York.
Regarding the Trustee
The indentures will limit the right of
the trustee, should it become a creditor of the Company, to obtain payment of claims or secure its claims.
The trustee will be permitted to engage
in certain other transactions. However, if the trustee, acquires any conflicting interest, and there is a default under the debt
securities of any series for which they are trustee, the trustee must eliminate the conflict or resign.
Subordinated Debt Securities
Payment on subordinated debt securities
will, to the extent provided in the indenture, be subordinated in right of payment to the prior payment in full of all of the Company's
senior indebtedness. Subordinated debt securities also are effectively subordinated to all debt and other liabilities, including
trade payables and lease obligations, if any, of the Company's subsidiaries.
Upon any distribution of the Company's
assets upon any dissolution, winding up, liquidation or reorganization, the payment of the principal of and interest on subordinated
debt securities will be subordinated in right of payment to the prior payment in full in cash or other payment satisfactory to
the holders of senior indebtedness of all senior indebtedness. In the event of any acceleration of the subordinated debt securities
because of an event of default, the holders of any senior indebtedness would be entitled to payment in full in cash or other payment
satisfactory to such holders of all senior indebtedness obligations before the holders of subordinated debt securities are entitled
to receive any payment or distribution. The indentures will require the Company to promptly notify holders of designated senior
indebtedness if payment of subordinated debt securities is accelerated because of an event of default.
The Company may not make any payment on
subordinated debt securities, including upon redemption at the option of the holder of any subordinated debt securities or at the
Company's option, if:
|
·
|
a default in the payment of the principal, premium, if any, interest, rent or other obligations in respect of designated senior
indebtedness occurs and is continuing beyond any applicable period of grace, which is called a "payment default"; or
|
|
·
|
a default other than a payment default on any designated senior indebtedness occurs and is continuing that permits holders
of designated senior indebtedness to accelerate its maturity, and the trustee receives notice of such default, which is called
a "payment blockage notice" from the Company or any other person permitted to give such notice under the indenture, which
is called a "non-payment default".
|
The Company may resume payments and distributions
on subordinated debt securities:
|
·
|
in the case of a payment default, upon the date on which such default is cured or waived or ceases to exist; and
|
|
·
|
in the case of a non-payment default, the earlier of the date on which such nonpayment default is cured or waived or ceases
to exist and 179 days after the date on which the payment blockage notice is received by the trustee, if the maturity of the designated
senior indebtedness has not been accelerated.
|
No new period of payment blockage may be
commenced pursuant to a payment blockage notice unless 365 days have elapsed since the initial effectiveness of the immediately
prior payment blockage notice and all scheduled payments of principal, premium and interest, including any liquidated damages,
on the notes that have come due have been paid in full in cash. No non-payment default that existed or was continuing on the date
of delivery of any payment blockage notice shall be the basis for any later payment blockage notice unless the non-payment default
is based upon facts or events arising after the date of delivery of such payment blockage notice.
If the trustee or any holder of the notes
receives any payment or distribution of the Company's assets in contravention of the subordination provisions on subordinated debt
securities before all senior indebtedness is paid in full in cash, property or securities, including by way of set-off, or other
payment satisfactory to holders of senior indebtedness, then such payment or distribution will be held in trust for the benefit
of holders of senior indebtedness or their representatives to the extent necessary to make payment in full in cash or payment satisfactory
to the holders of senior indebtedness of all unpaid senior indebtedness.
In the event of the Company's bankruptcy,
dissolution or reorganization, holders of senior indebtedness may receive more, ratably, and holders of subordinated debt securities
may receive less, ratably, than the Company's other creditors (including the Company's trade creditors). This subordination will
not prevent the occurrence of any event of default under the indenture.
Unless the Company informs you otherwise
in the prospectus supplement, the Company will not be prohibited from incurring debt, including senior indebtedness, under any
indenture relating to subordinated debt securities. The Company may from time to time incur additional debt, including senior indebtedness.
The Company is obligated to pay reasonable
compensation to the trustee and to indemnify the trustee against certain losses, liabilities or expenses incurred by the trustee
in connection with its duties relating to subordinated debt securities. The trustee’s claims for these payments will generally
be senior to those of noteholders in respect of all funds collected or held by the trustee.
Certain Definitions
"indebtedness" means:
(1) all indebtedness, obligations and other liabilities
for borrowed money, including overdrafts, foreign exchange contracts, currency exchange agreements, interest rate protection agreements,
and any loans or advances from banks, or evidenced by bonds, debentures, notes or similar instruments, other than any account payable
or other accrued current liability or obligation incurred in the ordinary course of business in connection with the obtaining of
materials or services;
(2) all reimbursement obligations and other liabilities
with respect to letters of credit, bank guarantees or bankers’ acceptances;
(3) all obligations and liabilities in respect of
leases required in conformity with generally accepted accounting principles to be accounted for as capitalized lease obligations
on the Company's balance sheet;
(4) all obligations and liabilities, contingent or
otherwise, as lessee under leases for facility equipment (and related assets leased together with such equipment) and under any
lease or related document (including a purchase agreement, conditional sale or other title retention or synthetic lease agreement)
in connection with the lease of real property or improvement thereon (or any personal property included as part of any such lease)
which provides that such Person is contractually obligated to purchase or cause a third party to purchase the leased property or
pay an agreed upon residual value of the leased property, including the obligations under such lease or related document to purchase
or cause a third party to purchase such leased property (whether or not such lease transaction is characterized as an operating
lease or a capitalized lease in accordance with GAAP) or pay an agreed upon residual value of the leased property to the lessor;
(5) all obligations with respect to an interest rate
or other swap, cap or collar agreement or other similar instrument or agreement or foreign currency hedge, exchange, purchase agreement
or other similar instrument or agreement;
(6) all direct or indirect guaranties or similar agreements
in respect of, and the Company's obligations or liabilities to purchase, acquire or otherwise assure a creditor against loss in
respect of, indebtedness, obligations or liabilities of others of the type described in (1) through (5) above;
(7) any indebtedness or other obligations described
in (1) through (6) above secured by any mortgage, pledge, lien or other encumbrance existing on property which is owned or held
by the Company; and
(8) any and all refinancings, replacements, deferrals,
renewals, extensions and refundings of, or amendments, modifications or supplements to, any indebtedness, obligation or liability
of the kind described in clauses (1) through (7) above.
"senior indebtedness" means the
principal, premium, if any, interest, including any interest accruing after bankruptcy, and rent or termination payment on or other
amounts due on the Company's current or future indebtedness, whether created, incurred, assumed, guaranteed or in effect guaranteed
by the Company, including any deferrals, renewals, extensions, refundings, amendments, modifications or supplements to the above.
However, senior indebtedness does not include:
|
·
|
indebtedness that expressly provides that it shall not be senior in right of payment to subordinated debt securities or expressly
provides that it is on the same basis or junior to subordinated debt securities;
|
|
·
|
the Company's indebtedness to any of the Company's majority-owned subsidiaries; and
|
|
·
|
subordinated debt securities.
|
DESCRIPTION OF PREFERRED
STOCK
As of the date of this prospectus, the
Company has authorized 1,666,667 shares of preferred stock, par value $.0001 per share, none of which are outstanding. Under the
Company's Restated Certificate of Incorporation, the Company's Board of Directors is authorized to issue shares of the Company's
preferred stock from time to time, in one or more classes or series, without stockholder approval. Prior to the issuance of shares
of each series, the Board of Directors is required by the General Corporation Law of the State of Delaware to adopt resolutions
and file a Certificate of Designation with the Secretary of State of the State of Delaware, fixing for each such series the designations,
powers, preferences, rights, qualifications, limitations and restrictions of the shares of such series. Any exercise of the Company's
Board of Directors of its rights to do so may affect the rights and entitlements of the holders of the Company's common stock as
set forth below.
The Company's Board of Directors could
authorize the issuance of shares of preferred stock with terms and conditions which could have the effect of discouraging a takeover
or other transaction which holders of some, or a majority, of such shares might believe to be in their best interests or in which
holders of some, or a majority, of such shares might receive a premium for their shares over the then-market price of such shares.
General
Subject to limitations prescribed by the
General Corporation Law of the State of Delaware, the Company's Restated Certificate of Incorporation and the Company's Amended
and Restated Bylaws ("Bylaws"), the Company's Board of Directors is authorized to fix the number of shares constituting
each series of preferred stock and the designations, powers, preferences, rights, qualifications, limitations and restrictions
of the shares of such series, including such provisions as may be desired concerning voting, redemption, dividends, dissolution
or the distribution of assets, conversion or exchange, and such other subjects or matters as may be fixed by resolution of the
Board of Directors. Each series of preferred stock that the Company offers under this prospectus will, when issued, be fully paid
and nonassessable and will not have, or be subject to, any preemptive or similar rights.
The applicable prospectus supplement(s)
will describe the following terms of the series of preferred stock in respect of which this prospectus is being delivered:
|
·
|
the title and stated value of the preferred stock;
|
|
·
|
the number of shares of the preferred stock offered, the liquidation preference per share and the purchase price of the preferred
stock;
|
|
·
|
the dividend rate(s), period(s) and/or payment date(s) or the method(s) of calculation for dividends;
|
|
·
|
whether dividends shall be cumulative or non-cumulative and, if cumulative, the date from which dividends on the preferred
stock shall accumulate;
|
|
·
|
the procedures for any auction and remarketing, if any, for the preferred stock;
|
|
·
|
the provisions for a sinking fund, if any, for the preferred stock;
|
|
·
|
the provisions for redemption, if applicable, of the preferred stock;
|
|
·
|
any listing of the preferred stock on any securities exchange or market;
|
|
·
|
the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock or another series
of the Company's preferred stock, including the conversion price (or its manner of calculation) and conversion period;
|
|
·
|
the terms and conditions, if applicable, upon which preferred stock will be exchangeable into the Company's debt securities,
including the exchange price, or its manner of calculation, and exchange period;
|
|
·
|
voting rights, if any, of the preferred stock; a discussion of any material and/or special U.S. federal income tax considerations
applicable to the preferred stock;
|
|
·
|
whether interests in the preferred stock will be represented by depositary shares;
|
|
·
|
the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution
or winding up of the Company's affairs;
|
|
·
|
any limitations on issuance of any series of preferred stock ranking senior to or on a parity with the preferred stock as to
dividend rights and rights upon liquidation, dissolution or winding up of the Company's affairs; and
|
|
·
|
any other specific terms, preferences, rights, limitations or restrictions on the preferred stock.
|
Unless otherwise specified in the prospectus
supplement, the preferred stock will, with respect to dividend rights and rights upon liquidation, dissolution or winding up of
the Company rank:
|
·
|
senior to all classes or series of the Company's common stock, and to all equity securities issued by the Company the terms
of which specifically provide that such equity securities rank junior to the preferred stock with respect to dividend rights or
rights upon the liquidation, dissolution or winding up of the Company;
|
|
·
|
on a parity with all equity securities issued by the Company that do not rank senior or junior to the preferred stock with
respect to dividend rights or rights upon the liquidation, dissolution or winding up of the Company; and
|
|
·
|
junior to all equity securities issued by the Company the terms of which do not specifically provide that such equity securities
rank on a parity with or junior to the preferred stock with respect to dividend rights or rights upon the liquidation, dissolution
or winding up of the Company (including any entity with which the Company may be merged or consolidated or to which all or substantially
all of the Company's assets may be transferred or which transfers all or substantially all of the Company's assets).
|
As used for these purposes, the term "equity
securities" does not include convertible debt securities.
Transfer Agent and Registrar
The transfer agent and registrar for any
series of preferred stock will be set forth in the applicable prospectus supplement.
DESCRIPTION OF COMMON
STOCK
This description of the Company's common
stock is a summary. You should keep in mind, however, that it is the Company's Restated Certificate of Incorporation and Bylaws,
and not this summary, which define any rights you may acquire as a stockholder. There may be other provisions in such documents
which are also important to you. You should read such documents for a full description of the terms of the Company's common stock,
along with the applicable provisions of Delaware law.
As of the date of this prospectus, the
Company has authorized 33.3 million shares of common stock, par value $0.0001 per share. As of May 7, 2014, there were 11,282,982
shares of common stock outstanding, which does not include:
|
·
|
approximately 555 thousand shares of the Company's common stock issuable upon the exercise of warrants outstanding as of May
7, 2014, at weighted average price of $71.46 per share (without giving effect to any of the anti dilution adjustment provisions
thereof);
|
|
·
|
approximately 165 thousand shares of the Company's common stock issuable upon the exercise of options outstanding as of May
7, 2014, at weighted average price of $47.16 per share (without giving effect to any of the anti dilution adjustment provisions
thereof);
|
|
·
|
approximately 79 thousand shares of common stock available for future grant under the Company's Third Amended and Restated
2008 Stock Incentive Plan, as amended and restated, as of June 1, 2012 (the "Current Plan"); and
|
|
·
|
approximately 894 thousand shares of common stock that will become available for future grant under the Company's Fourth Amended
and Restated 2008 Stock Incentive Plan upon the Company's stockholders' approval of the plan at the 2014 annual meeting of stockholders
to be held on May 22, 2014 (in addition to the approximately 79 thousand available under the Company's Current Plan). Such 894
thousand shares include approximately 325 thousand shares issuable upon exercise of options at a weighted average price of $6.39
per share and approximately 30 thousand restricted stock awards, each of which were approved by the Board of Directors of the Company
and are subject to stockholder approval at the Company's 2014 annual meeting of stockholders.
|
Subject to any preferential rights of any
preferred stock created by the Company's Board of Directors, as a holder of the Company's common stock you are entitled to such
dividends as the Company's Board of Directors may declare from time to time out of funds that the Company can legally use to pay
dividends. The holders of common stock possess exclusive voting rights, except to the extent the Company's Board of Directors specifies
voting power for any preferred stock that may be issued in the future.
As a holder of the Company's common
stock, you are entitled to one vote for each share of common stock and do not have any right to cumulative voting in the
election of directors. Upon the Company's liquidation, dissolution or winding-up, you will be entitled to receive on a
proportionate basis any assets remaining after provision for payment of creditors and after payment of any liquidation
preferences to holders of preferred stock. Holders of the Company's common stock have no preemptive rights and no conversion
rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company's common
stock. All the outstanding shares of common stock are, and the shares offered by this prospectus, when issued and paid for,
will be, validly issued, fully paid and nonassessable. The Company's common stock is quoted on The NASDAQ Global Market under
the trading symbol "ANIP."
Anti-Takeover Provisions
As a corporation organized under the laws
of the State of Delaware, the Company is subject to Section 203 of the General Corporation Law of the State of Delaware, which
restricts the Company's ability to enter into business combinations with an interested stockholder or a stockholder owning 15%
or more of the Company's outstanding voting stock, or that stockholder’s affiliates or associates, for a period of three
years. These restrictions do not apply if:
|
·
|
before becoming an interested stockholder, the Company's Board of Directors approves either the business combination or the
transaction in which the stockholder becomes an interested stockholder;
|
|
·
|
upon consummation of the transaction in which the stockholder becomes an interested stockholder, the interested stockholder
owns at least 85% of the Company's voting stock outstanding at the time the transaction commenced, subject to exceptions; or
|
|
·
|
on or after the date a stockholder becomes an interested stockholder, the business combination is both approved by the Company's
Board of Directors and authorized at an annual or special meeting of the Company's stockholders by the affirmative vote of at least
two-thirds of the outstanding voting stock not owned by the interested stockholder.
|
Number of Directors; Removal
The Company's Bylaws provide that the Company's
Board of Directors shall consist of at least one director and may consist of such larger number as may be determined, from time-to-time,
by the Board of Directors. The Company's Bylaws provide that directors may be removed with or without cause by the affirmative
vote of holders of a majority of the total voting power of all outstanding securities.
This provision and the Board of Directors’
right to issue shares of the Company's preferred stock from time to time, in one or more classes or series without stockholder
approval are intended to enhance the likelihood of continuity and stability in the composition of the policies formulated by the
Company's Board of Directors. These provisions are also intended to discourage some tactics that may be used in proxy fights.
Transfer Agent and Registrar
The Transfer Agent and Registrar for the
Company's common stock is Continental Stock Transfer & Trust Company.
DESCRIPTION OF WARRANTS
Outstanding Warrants
As of May 7, 2014, approximately 555 thousand
shares of common stock were issuable upon the exercise of outstanding warrants, at a weighted average exercise price of $71.46.
As of May 7, 2014, the following warrants
were outstanding:
|
·
|
warrants to purchase an aggregate of 73,333 shares of the Company's common stock at an exercise price of $90.00 per share issued
to various institutional investors and the Company's placement agent in connection with the Company's registered direct offering
completed on August 13, 2009;
|
|
·
|
warrants to purchase an aggregate of 144,508 shares of the Company's common stock at an exercise price of $74.88 per share
issued to various institutional investors in connection with the registered direct offering completed on March 8, 2010;
|
|
·
|
warrants to purchase an aggregate of 5,780 shares of the Company's common stock at an exercise price of $77.76 per share issued
to the Company's placement agent in connection with the Company's registered direct offering completed on March 8, 2010;
|
|
·
|
warrants to purchase an aggregate of 99,088 shares of the Company's common stock at an exercise price of $88.20 per share issued
to various institutional investors in connection with the Company's registered direct offering completed on June 23, 2010;
|
|
·
|
warrants to purchase an aggregate of 5,945 shares of the Company's common stock at an exercise price of $94.68 per share issued
to the Company's placement agent in connection with the Company's registered direct offering completed on June 23, 2010;
|
|
·
|
warrants to purchase an aggregate of 147,058 shares of the Company's common stock at an exercise price of $72.00 per share
issued to various institutional investors in connection with the Company's registered direct offering completed on December 30,
2010;
|
|
·
|
warrants to purchase an aggregate of 8,823 shares of the Company's common stock at an exercise price of $76.50 per share issued
to the Company's placement agent in connection with the Company's registered direct offering completed on December 30, 2010;
|
|
·
|
warrants to purchase an aggregate of 6,777 shares of the Company's common stock at an exercise price of $92.88 per share issued
to the Company's placement agent in connection with the Company's registered direct offering completed on March 8, 2011; and
|
|
·
|
warrants to purchase an aggregate of 63,333 shares of the Company's common stock at an exercise price of $9.00, per share issued
to various institutional investors in connection with the Company's registered direct offering on August 20, 2012.
|
The Company may issue, in one or
more series, debt warrants to purchase debt securities, as well as equity warrants to purchase preferred stock or common stock.
The warrants may be issued independently or together with any securities and may be attached to or separate from the securities.
If the warrants are issued pursuant to warrant agreements, the Company will so specify in the prospectus supplement relating to
the warrants being offered pursuant to the prospectus supplement. While the following the terms described below will apply generally
to any warrants the Company may offer, the Company will describe the particular terms of any series of warrants in the applicable
prospectus supplement. The terms of any warrants offered under a prospectus supplement for a particular series of warrants may
specify different or additional terms than those specified below.
Debt Warrants
The applicable prospectus supplement will
describe the terms of debt warrants offered, the warrant agreement relating to the debt warrants and the debt warrant certificates
representing the debt warrants, including the following:
|
·
|
the title of the debt warrants;
|
|
·
|
the aggregate number of the debt warrants;
|
|
·
|
the price or prices at which the debt warrants will be issued;
|
|
·
|
the designation, aggregate principal amount and terms of the debt securities purchasable upon exercise of the debt warrants,
and the procedures and conditions relating to the exercise of the debt warrants;
|
|
·
|
the designation and terms of any related debt securities with which the debt warrants are issued, and the number of the debt
warrants issued with each debt security;
|
|
·
|
the principal amount of debt securities purchasable upon exercise of each debt warrant;
|
|
·
|
the date on which the right to exercise the debt warrants will commence, and the date on which this right will expire;
|
|
·
|
the maximum or minimum number of debt warrants which may be exercised at any time;
|
|
·
|
a discussion of any material federal income tax considerations; and
|
|
·
|
any other terms of the debt warrants and terms, procedures and limitations relating to the exercise of debt warrants.
|
Debt warrant certificates will be exchangeable
for new debt warrant certificates of different denominations, and debt warrants may be exercised at the corporate trust office
of the warrant agent or any other office indicated in the prospectus supplement, by delivering the properly completed and duly
executed warrant certificate and paying the required amount to the warrant agent in immediately available funds. Prior to the exercise
of their debt warrants, holders of debt warrants will not have any of the rights of holders of the debt securities purchasable
upon exercise and will not be entitled to payment of principal of or any premium, if any, or interest on the debt securities purchasable
upon exercise.
Equity Warrants
The applicable prospectus supplement will
describe the following terms of equity warrants offered:
|
·
|
the title of the equity warrants;
|
|
·
|
the securities (i.e., preferred stock or common stock) for which the equity warrants are exercisable;
|
|
·
|
the price or prices at which the equity warrants will be issued;
|
|
·
|
if applicable, the designation and terms of the preferred stock or common stock with which the equity warrants are issued,
and the number of equity warrants issued with each share of preferred stock or common stock; and
|
|
·
|
any other terms of the equity warrants, including terms, procedures and limitations relating to the exchange and exercise of
equity warrants.
|
Holders of equity warrants will not be
entitled, by virtue of being such holders, to vote, consent, receive dividends, receive notice as stockholders with respect to
any meeting of stockholders for the election of the Company's directors or any other matter, or to exercise any rights whatsoever
as the Company's stockholders.
The exercise price payable and the number
of shares of common stock or preferred stock purchasable upon the exercise of each equity warrant will be subject to adjustment
in certain events, including the issuance of a stock dividend to holders of common stock or preferred stock or a stock split, reverse
stock split, combination, subdivision or reclassification of common stock or preferred stock. In lieu of adjusting the number of
shares of common stock or preferred stock purchasable upon exercise of each equity warrant, the Company may elect to adjust the
number of equity warrants. No adjustments in the number of shares purchasable upon exercise of the equity warrants will be required
until cumulative adjustments require an adjustment of at least 1% thereof. The Company may, at its option, reduce the exercise
price at any time. No fractional shares will be issued upon exercise of equity warrants, but the Company will pay the cash value
of any fractional shares otherwise issuable. Notwithstanding the foregoing, in case of any consolidation, merger, or sale or conveyance
of the Company's property as an entirety or substantially as an entirety, the holder of each outstanding equity warrant shall have
the right to the kind and amount of shares of stock and other securities and property, including cash, receivable by a holder of
the number of shares of common stock or preferred stock into which the equity warrant was exercisable immediately prior to the
transaction.
Exercise of Warrants
Each warrant will entitle the holder to
purchase for cash such principal amount of securities or shares of stock at such exercise price as shall in each case be set forth
in, or be determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised
at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants
offered thereby. After the close of business on the expiration date, unexercised warrants will become void.
The warrants may be exercised as set forth
in the prospectus supplement relating to the warrants offered. Upon receipt of payment and the taking of other action specified
in the applicable prospectus supplement, the Company will, as soon as practicable, forward the securities purchasable upon exercise.
If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued
for the remaining warrants.
Each warrant agent will act solely as the
Company's agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with
any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant
agent will have no duty or responsibility in case of any default by the Company under the applicable warrant agreement or warrant,
including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon the Company. Any
holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate
legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.
Outstanding Warrants Under This Prospectus
None of the warrants described in this
section have been listed for trading on any securities exchange. The number of shares issuable upon exercise of any of the warrants
issued prior to June 1, 2012, as well as the exercise prices and any trading thresholds triggering optional redemption and redemption
prices for such warrants, have been adjusted for the 1-for-6 reverse stock split that was made effective June 1, 2012 and the 1-for-6
reverse stock split that was made effective July 17, 2013.
As of May 7, 2014, warrants to purchase
133,328 shares of the Company's common stock have been exercised, at $9.00 per share.
Warrants Issued on August 13, 2009
On August 13, 2009, the Company issued
warrants to purchase an aggregate of up to 73,333 shares of the Company's common stock to various institutional investors and the
Company's placement agent in connection with the Company's registered direct offering. The warrants have an exercise price of $90.00.
Warrants to purchase an aggregate of up to 6,667 shares of the Company's common stock expire on June 9, 2014. Warrants to purchase
an aggregate of up to 66,666 shares of the Company's common stock expire on August 12, 2014.
Exercisability
. The number
of warrant shares that may be acquired by any holder upon any exercise of the warrant is limited to the extent necessary to insure
that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by such holder
and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder’s
for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, does not exceed 4.9% of the total number
of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise),
or beneficial ownership limitation. The holder may elect to increase or decrease this beneficial ownership limitation upon 61 days’
prior notice. The beneficial ownership limitation, however, may not exceed 9.99% of the total number of issued and outstanding
shares of common stock (including for such purpose the shares of common stock issuable upon such exercise).
Manner of Exercise
. Holders of the
warrants may exercise their warrants to purchase shares of the Company's common stock on or before the expiration date by delivering
(i) notice of exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise
provisions with respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant
is being exercised. Warrants may be exercised in whole or in part, but only for full shares of common stock. The Company provides
certain buy-in rights to a holder if the Company fails to deliver the shares of common stock underlying the warrants by the third
trading day after the date on which delivery of the stock certificate is required by the warrant. The buy-in rights apply if after
the third trading day on which delivery of the stock certificate is required by the warrant, the holder purchases (in an open market
transaction or otherwise) shares of the common stock to deliver in satisfaction of a sale by the holder of the warrant shares that
the holder anticipated receiving from the Company upon exercise of the warrant. In this event, the Company must:
|
·
|
pay in cash to the holder the amount equal to the excess (if any) of the buy-in price over the product of (A) such number of
shares of common stock, times (B) the price at which the sell order giving rise to holder’s purchase obligation was executed;
and
|
|
·
|
at the election of holder, either (A) reinstate the portion of the warrant as to such number of shares of common stock, or
(B) deliver to the holder the number of common stock that would have been issued had the Company timely complied with its exercise
and delivery obligations under the warrants.
|
In addition, the warrant holders are entitled
to a “cashless exercise” option if, at any time of exercise, there is no effective registration statement registering,
or no current prospectus available for, the issuance or resale of the shares of common stock underlying the warrants. This option
entitles the warrant holders to elect to receive fewer shares of common stock without paying the cash exercise price. The number
of shares to be issued is determined by a formula set forth in the warrant.
The shares of common stock issuable on
exercise of the warrants must be, when issued and paid for in accordance with the warrants, duly authorized, validly issued and
fully paid and non-assessable.
Fundamental Transaction
. If, at
any time while the warrants are outstanding, (i) the Company consolidates or merges with or into another corporation, (ii) the
Company sells, leases, licenses, assigns, transfers, conveys or otherwise disposes of all or substantially all of its assets, (iii)
any purchase offer, tender offer or exchange offer (whether by the Company or another individual or entity) is completed pursuant
to which holders of the Company's common stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the Company's outstanding common stock, (iv) the Company effects
any reclassification or recapitalization of its common stock or any compulsory share exchange pursuant to which the Company's common
stock is converted into or exchanged for other securities, cash or property, or (v) the Company consummates a stock or share purchase
agreement or other business combination with another person or entity whereby such other person or entity acquires more than 50%
of the outstanding shares of the Company's common stock (each, a “Fundamental Transaction”), then upon any subsequent
exercise of the warrants, the holders thereof have the right to receive the same amount and kind of securities, cash or property
as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior
to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any
additional consideration payable as part of the Fundamental Transaction. Any successor to the Company or surviving entity must
assume the obligations under the warrant.
Certain Adjustments
. The exercise
price is subject to certain adjustments set forth in the warrants, such as in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the Company's common stock.
Delivery of Certificates
. Upon the
holder’s exercise of a warrant, the Company must promptly, but in no event later than three trading days after the exercise
date, issue and deliver, or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise
of the warrant. In addition, the Company must, if the holder provides the necessary information to the Company, issue and deliver
the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)
or another established clearing corporation performing similar functions.
Notice of Corporate Action
. The
Company must provide at least 20 days prior notice to holders of the warrants to provide them with the opportunity to exercise
their warrants and hold common stock in order to participate in or vote on the following corporate events:
|
·
|
if the Company takes a record of the holders of the Company's common stock for the purpose of entitling them to receive a dividend
or other distribution, or any right to subscribe for or purchase any shares of stock of any class or any other right;
|
|
·
|
if the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any transaction
that would be deemed a Fundamental Transaction; or
|
|
·
|
a voluntary dissolution, liquidation or winding up of the Company.
|
Additional Provisions
. The Company
is not required to issue fractional shares upon the exercise of the warrants. Except as otherwise provided in the warrants or by
virtue of such holder’s ownership of shares of the Company's common stock, no holder of the warrants possesses any rights
as a stockholder under those warrants until the holder exercises those warrants. Subject to applicable securities laws, the warrants
may be transferred in accordance with the terms set forth in the warrants. Any term of the warrants may be amended or waived with
the Company's written consent and the written consent of the holders of warrants at least equal to 67% of the Company's common
stock issuable upon exercise of the warrants.
Warrants Issued on March 8, 2010
On March 8, 2010, the Company issued warrants
to purchase an aggregate of up to 144,508 shares of the Company's common stock to various institutional investors in connection
with the Company's registered direct offering. The warrants have an exercise price of $74.88 and an expiration date of September
8, 2015.
Exercisability
. The number
of warrant shares that may be acquired by any holder upon any exercise of the warrant is limited to the extent necessary to insure
that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by such holder
and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder’s
for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, does not exceed 9.99% of the total
number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such
exercise), or beneficial ownership limitation. The holder may elect to increase or decrease this beneficial ownership limitation
upon 61 days’ prior notice.
Manner of Exercise
. Holders of the
warrants may exercise their warrants to purchase shares of the Company's common stock on or before the expiration date by delivering
(i) notice of exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise
provisions with respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant
is being exercised. Warrants may be exercised in whole or in part, but only for full shares of common stock. The Company provides
certain buy-in rights to a holder if the Company fails to deliver the shares of common stock underlying the warrants by the third
trading day after the date on which delivery of the stock certificate is required by the warrant. The buy-in rights apply if after
the third trading day on which delivery of the stock certificate is required by the warrant, the holder purchases (in an open market
transaction or otherwise) shares of the common stock to deliver in satisfaction of a sale by the holder of the warrant shares that
the holder anticipated receiving from the Company upon exercise of the warrant. In this event, the Company must:
|
·
|
pay in cash to the holder the amount equal to the excess (if any) of the buy-in price over the product of (A) such number of
shares of common stock, times (B) the price at which the sell order giving rise to holder’s purchase obligation was executed;
and
|
|
·
|
at the election of holder, either (A) reinstate the portion of the warrant as to such number of shares of common stock, or
(B) deliver to the holder the number of common stock that would have been issued had the Company timely complied with its exercise
and delivery obligations under the warrants.
|
In addition, the warrants may be exercised,
in whole or in part, at such time by means of a “cashless exercise” in which the holder of such warrants is entitled
to receive the Company's common stock determined according to the formula set forth in the warrant.
The shares of common stock issuable on
exercise of the warrants must be, when issued and paid for in accordance with the warrants, duly authorized, validly issued and
fully paid and non-assessable.
Fundamental Transaction
. If, at
any time while the warrants are outstanding, (i) the Company consolidates or merges with or into another corporation, (ii) the
Company sells, leases, licenses, assigns, transfers, conveys or otherwise disposes of all or substantially all of its assets, (iii)
any purchase offer, tender offer or exchange offer (whether by the Company or another individual or entity) is completed pursuant
to which holders of the Company's common stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the Company's outstanding common stock, (iv) the Company effects
any reclassification or recapitalization of its common stock or any compulsory share exchange pursuant to which the Company's common
stock is converted into or exchanged for other securities, cash or property, (v) the Company consummates a stock or share purchase
agreement or other business combination with another person or entity whereby such other person or entity acquires more than 50%
of the outstanding shares of the Company's common stock, or (vi) the liquidation, bankruptcy, insolvency, dissolution or winding-up
(or the occurrence of any analogous proceeding) affecting the Company (each, a “Fundamental Transaction”), then upon
any subsequent exercise of the warrants, the holders thereof have the right to receive the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been,
immediately prior to such Fundamental Transaction, the holder of shares of the Company's common stock then issuable upon exercise
of the warrant, and any additional consideration payable as part of the Fundamental Transaction. Any successor to the Company or
surviving entity must assume the obligations under the warrant.
Certain Adjustments
. The exercise
price is subject to certain adjustments set forth in the warrants, such as in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the Company's common stock.
Delivery of Certificates
. Upon the
holder’s exercise of a warrant, the Company must promptly, but in no event later than three trading days after the exercise
date, issue and deliver, or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise
of the warrant. In addition, the Company must, if the holder provides the necessary information to the Company, issue and deliver
the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)
or another established clearing corporation performing similar functions.
Notice of Corporate Action
. The
Company must provide at least 20 days prior notice to holders of the warrants to provide them with the opportunity to exercise
their warrants and hold common stock in order to participate in or vote on the following corporate events:
|
·
|
if the Company takes a record of the holders of the Company's common stock for the purpose of entitling them to receive a dividend
or other distribution, or any right to subscribe for or purchase any shares of stock of any class or any other right;
|
|
·
|
if the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any transaction
that would be deemed a Fundamental Transaction; or
|
|
·
|
a voluntary dissolution, liquidation or winding up of the Company.
|
Additional Provisions
. The Company
is not required to issue fractional shares upon the exercise of the warrants. Except as otherwise provided in the warrants or by
virtue of such holder’s ownership of shares of the Company's common stock, no holder of the warrants possesses any rights
as a stockholder under those warrants until the holder exercises those warrants. Subject to applicable securities laws, the warrants
may be transferred in accordance with the terms set forth in the warrants. Any term of the warrants may be amended or waived with
the Company's written consent and the written consent of the holders of warrants.
Warrants Issued on June 23, 2010 and December 30, 2010
On June 23, 2010, the Company issued warrants
to purchase an aggregate of up to 99,088 shares of the Company's common stock to various institutional investors in connection
with the Company's registered direct offering. The warrants have an exercise price of $88.20 and an expiration date of June 23,
2015.
On December 30, 2010, the Company issued
warrants to purchase an aggregate of up to 147,058 shares of the Company's common stock to various institutional investors in connection
with the Company's registered direct offering. The warrants have an exercise price of $72.00 and an expiration date of December
30, 2015.
Exercisability
. The number
of warrant shares that may be acquired by any holder upon any exercise of the warrant is limited to the extent necessary to insure
that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by such holder
and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder’s
for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, does not exceed 4.99% of the total
number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such
exercise), or beneficial ownership limitation. The holder may elect to increase or decrease this beneficial ownership limitation
upon 61 days’ prior notice. The beneficial ownership limitation, however, may not exceed 9.99% of the total number of issued
and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise).
Manner of Exercise
. Holders of the
warrants may exercise their warrants to purchase shares of the Company's common stock on or before the expiration date by delivering
(i) notice of exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise
provisions with respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant
is being exercised. Warrants may be exercised in whole or in part, but only for full shares of common stock. The Company provides
certain buy-in rights to a holder if the Company fails to deliver the shares of common stock underlying the warrants by the third
trading day after the date on which delivery of the stock certificate is required by the warrant. The buy-in rights apply if after
the third trading day on which delivery of the stock certificate is required by the warrant, the holder purchases (in an open market
transaction or otherwise) shares of the common stock to deliver in satisfaction of a sale by the holder of the warrant shares that
the holder anticipated receiving from the Company upon exercise of the warrant. In this event, the Company must:
|
·
|
pay in cash to the holder the amount equal to the excess (if any) of the buy-in price over the product of (A) such number of
shares of common stock, times (B) the price at which the sell order giving rise to holder’s purchase obligation was executed;
and
|
|
·
|
at the election of holder, either (A) reinstate the portion of the warrant as to such number of shares of common stock, or
(B) deliver to the holder the number of common stock that would have been issued had the Company timely complied with its exercise
and delivery obligations under the warrants.
|
In addition, the warrant holders are entitled
to a “cashless exercise” option if, at any time of exercise, there is no effective registration statement registering,
or no current prospectus available for, the issuance or resale of the shares of common stock underlying the warrants. This option
entitles the warrant holders to elect to receive fewer shares of common stock without paying the cash exercise price. The number
of shares to be issued is determined by a formula set forth in the warrant.
The shares of common stock issuable on
exercise of the warrants must be, when issued and paid for in accordance with the warrants, duly authorized, validly issued and
fully paid and non-assessable.
Fundamental Transaction
. If, at
any time while the warrants are outstanding, (i) the Company consolidates or merges with or into another corporation, (ii) the
Company sells, leases, licenses, assigns, transfers, conveys or otherwise disposes of all or substantially all of its assets, (iii)
any purchase offer, tender offer or exchange offer (whether by the Company or another individual or entity) is completed pursuant
to which holders of the Company's common stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the Company's outstanding common stock, (iv) the Company effects
any reclassification or recapitalization of its common stock or any compulsory share exchange pursuant to which the Company's common
stock is converted into or exchanged for other securities, cash or property, or (v) the Company consummates a stock or share purchase
agreement or other business combination with another person, entity or group of persons or entities whereby such other person,
entity or group of persons or entities acquires more than 50% of the outstanding shares of the Company's common stock (each, a
“Fundamental Transaction”), then upon any subsequent exercise of the warrants, the holders thereof have the right to
receive the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence
of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of shares of the
Company's common stock then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental
Transaction. Any successor to the Company or surviving entity must assume the obligations under the warrant.
Certain Adjustments
. The exercise
price is subject to certain adjustments set forth in the warrants, such as in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the Company's common stock.
Delivery of Certificates
. Upon the
holder’s exercise of a warrant, the Company must promptly, but in no event later than three trading days after the exercise
date, issue and deliver, or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise
of the warrant. In addition, the Company must, if the holder provides the necessary information to the Company, issue and deliver
the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)
or another established clearing corporation performing similar functions.
Notice of Corporate Action
. The
Company must provide at least 20 days prior notice to holders of the warrants to provide them with the opportunity to exercise
their warrants and hold common stock in order to participate in or vote on the following corporate events:
|
·
|
if the Company takes a record of the holders of the Company's common stock for the purpose of entitling them to receive a dividend
or other distribution, or any right to subscribe for or purchase any shares of stock of any class or any other right;
|
|
·
|
if the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any transaction
that would be deemed a Fundamental Transaction; or
|
|
·
|
a voluntary dissolution, liquidation or winding up of the Company.
|
Additional Provisions
. The Company
is not required to issue fractional shares upon the exercise of the warrants. Except as otherwise provided in the warrants or by
virtue of such holder’s ownership of shares of the Company's common stock, no holder of the warrants possesses any rights
as a stockholder under those warrants until the holder exercises those warrants. Subject to applicable securities laws, the warrants
may be transferred in accordance with the terms set forth in the warrants. Any term of the warrants may be amended or waived with
the Company's written consent and the written consent of the holders of warrants at least equal to 67% of the Company's common
stock issuable upon exercise of the warrants.
Warrants Issued on August 20, 2012
On June 20, 2012, the Company issued warrants
to purchase an aggregate of up to 196,661 shares of the Company's common stock to various institutional investors in connection
with the Company's registered direct offering. The warrants have an exercise price of $9.00 and an expiration date of August 16,
2017.
Exercisability
. The number
of warrant shares that may be acquired by any holder upon any exercise of the warrant is limited to the extent necessary to insure
that, following such exercise (or other issuance), the total number of shares of common stock then beneficially owned by such holder
and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder’s
for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, does not exceed 4.99% of the total
number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such
exercise), or beneficial ownership limitation. The holder may elect to increase or decrease this beneficial ownership limitation
upon 61 days’ prior notice. The beneficial ownership limitation, however, may not exceed 9.99% of the total number of issued
and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise).
Manner of Exercise
. Holders of the
warrants may exercise their warrants to purchase shares of the Company's common stock on or before the expiration date by delivering
(i) notice of exercise, appropriately completed and duly signed, and (ii) if such holder is not utilizing the cashless exercise
provisions with respect to the warrants, payment of the exercise price for the number of shares with respect to which the warrant
is being exercised. Warrants may be exercised in whole or in part, but only for full shares of common stock. The Company provides
certain buy-in rights to a holder if the Company fails to deliver the shares of common stock underlying the warrants by the third
trading day after the date on which delivery of the common stock is required by the warrant. The buy-in rights apply if after the
third trading day on which delivery of the common stock is required by the warrant, the holder purchases (in an open market transaction
or otherwise) shares of the common stock to deliver in satisfaction of a sale by the holder of the warrant shares that the holder
anticipated receiving from the Company upon exercise of the warrant. In this event, the Company must:
|
·
|
pay in cash to the holder the amount equal to the excess (if any) of the buy-in price over the product of (A) such number of
shares of common stock, times (B) the price at which the sell order giving rise to holder’s purchase obligation was executed;
and
|
|
·
|
at the election of holder, either (A) reinstate the portion of the warrant as to such number of shares of common stock, or
(B) deliver to the holder the number of common stock that would have been issued had the Company timely complied with its exercise
and delivery obligations under the warrants.
|
In addition, the warrant holders are entitled
to a “cashless exercise” option if, at any time of exercise, there is no effective registration statement registering,
or no current prospectus available for, the issuance or resale of the shares of common stock underlying the warrants. This option
entitles the warrant holders to elect to receive fewer shares of common stock without paying the cash exercise price. The number
of shares to be issued is determined by a formula set forth in the warrant.
The shares of common stock issuable on
exercise of the warrants must be, when issued and paid for in accordance with the warrants, duly authorized, validly issued and
fully paid and non-assessable.
Fundamental Transaction
. If, at
any time while the warrants are outstanding, (i) the Company consolidates or merges with or into another corporation, (ii) the
Company sells, leases, licenses, assigns, transfers, conveys or otherwise disposes of all or substantially all of its assets, (iii)
any purchase offer, tender offer or exchange offer (whether by the Company or another individual or entity) is completed pursuant
to which holders of the Company's common stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the Company's outstanding common stock, (iv) the Company effects
any reclassification or recapitalization of its common stock or any compulsory share exchange pursuant to which the Company's common
stock is converted into or exchanged for other securities, cash or property, or (v) the Company consummates a stock or share purchase
agreement or other business combination with another person, entity or group of persons or entities whereby such other person,
entity or group of persons or entities acquires more than 50% of the outstanding shares of the Company's common stock (each, a
“Fundamental Transaction”), then upon any subsequent exercise of the warrants, the holders thereof have the right to
receive the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence
of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of shares of the
Company's common stock then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental
Transaction. Any successor to the Company or surviving entity must assume the obligations under the warrant.
Certain Adjustments
. The exercise
price is subject to certain adjustments set forth in the warrants, such as in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the Company's common stock.
Subsequent Rights Offerings
. If
the Company grants, issues or sells any common stock equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of the Company's common stock (the “Purchase Rights”), then the holders of warrants
are entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the holder of warrants
could have acquired if the holder of warrants had held the number of shares of the Company's common stock acquirable upon complete
exercise of the warrants immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase
Rights, or, if no such record is taken, the date as of which the record holders of shares of the Company's common stock are determined
for the grant, issue or sale of such Purchase Rights. To the extent that such holder's right to participate in any such Purchase
Right would result in such holder exceeding the beneficial ownership limitation, then such holder cannot participate in such Purchase
Right to such extent and such Purchase Right to such extent is held in abeyance for the such holder until such time, if ever, as
its right thereto would not result in such exceeding the beneficial ownership limitation.
Pro Rata Distributions
. if the Company
declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of the
Company's common stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock
or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a “Distribution”), then the holders of warrants are entitled to participate in such
Distribution to the same extent that such holder would have participated therein if such holder had held the number of shares of
the Company's common stock acquirable upon complete exercise of such holder's warrants immediately before the date of which a record
is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of the Company's
common stock are to be determined for the participation in such Distribution. To the extent that such holder's right in any such
Distribution would result in such holder exceeding the beneficial ownership limitation, then such holder is not entitled to participate
in such Distribution to such extent and the portion of such Distribution is held in abeyance for the benefit of such holder until
such time, if ever, as its right thereto would not result in such holder exceeding the beneficial ownership limitation.
Delivery of Certificates
. Upon the
holder’s exercise of a warrant, the Company must promptly, but in no event later than three trading days after the exercise
date, issue and deliver, or cause to be issued and delivered, a certificate for the shares of common stock issuable upon exercise
of the warrant. In addition, the Company must, if the holder provides the necessary information to the Company, issue and deliver
the shares electronically through The Depository Trust Corporation through its Deposit Withdrawal Agent Commission System (DWAC)
or another established clearing corporation performing similar functions.
Notice of Corporate Action
. The
Company must provide at least 20 days prior notice to holders of the warrants to provide them with the opportunity to exercise
their warrants and hold common stock in order to participate in or vote on the following corporate events:
|
·
|
if the Company takes a record of the holders of the Company's common stock for the purpose of entitling them to receive a dividend
or other distribution, or any right to subscribe for or purchase any shares of stock of any class or any other right;
|
|
·
|
if the Company authorizes or approves, enters into any agreement contemplating, or solicits stockholder approval for any transaction
that would be deemed a Fundamental Transaction; or
|
|
·
|
a voluntary dissolution, liquidation or winding up of the Company.
|
Additional Provisions
. The Company
is not required to issue fractional shares upon the exercise of the warrants. Except as otherwise provided in the warrants or by
virtue of such holder’s ownership of shares of the Company's common stock, no holder of the warrants possesses any rights
as a stockholder under those warrants until the holder exercises those warrants. Subject to applicable securities laws, the warrants
may be transferred in accordance with the terms set forth in the warrants. Any term of the warrants may be amended or waived with
the Company's written consent and the written consent of the holders of warrants at least equal to 67% of the Company's common
stock issuable upon exercise of the warrants.
SELLING STOCKHOLDERS
This prospectus also
relates to the possible sale from time to time of up to 3,500,000 shares of the Company's common stock by certain of its stockholders,
who the Company refers to in this prospectus as the “selling stockholders.” The selling stockholders originally acquired
the shares of the Company's common stock included in this prospectus in connection with the Merger on June 19, 2013.
Information about the
selling stockholders will be set forth in an applicable prospectus supplement. The selling stockholders may from time to time offer
and sell such securities pursuant to this prospectus and any applicable prospectus supplement. Some of the selling stockholders
are affiliates of the Company.
An
applicable prospectus supplement will set forth the name of each selling stockholder, the nature of any position, office, or other
material relationship which any selling stockholder has had within the past three years with the Company or any of its predecessors
or affiliates, if any, the amount of the Company's common stock owned by each selling stockholder prior to the offering, the amount
of the Company's common stock which may be offered for each selling stockholder's account, and the amount and (if one percent or
more) the percentage of the Company's common stock to be owned by each selling stockholder after completion of the offering.
The
selling stockholders shall not sell any shares of the Company's common stock pursuant to this prospectus until the Company has
identified such selling stockholders and the shares of the Company's common stock which may be offered for resale by such selling
stockholders in a subsequent prospectus supplement. However, the selling stockholders may sell or transfer all or a portion of
their shares of common stock pursuant to any available exemption from the registration requirements of the Securities Act.
PLAN OF DISTRIBUTION
The Company or the selling stockholders
may sell the securities being offered by it in this prospectus pursuant to underwritten public offerings, negotiated transactions,
block trades or any combination of such methods. The Company or the selling stockholders may sell the securities to or through
underwriters, dealers, agents or directly to one or more purchasers. The Company and its agents reserve the right to accept and
to reject in whole or in part any proposed purchase of securities. A prospectus supplement or post-effective amendment, which the
Company will file each time the Company or the selling stockholders effect an offering of any securities, will provide the names
of any underwriters, dealers or agents, if any, involved in the sale of such securities, and any applicable fees, commissions,
or discounts to which such persons shall be entitled to in connection with such offering.
The Company, the selling stockholders and
its agents, dealers and underwriters, as applicable, may sell the securities being offered by the Company in this prospectus from
time to time in one or more transactions at:
|
·
|
a fixed price or prices, which may be changed;
|
|
·
|
market prices prevailing at the time of sale;
|
|
·
|
prices related to such prevailing market prices;
|
|
·
|
varying prices determined at the time of sale; or
|
The Company or the selling stockholders
may determine the price or other terms of the securities offered under this prospectus by use of an electronic auction. The Company
will describe how any auction will determine the price or any other terms, how potential investors may participate in the auction
and the nature of the underwriters’ obligations in the applicable prospectus supplement or amendment.
The Company or the selling stockholders
may solicit directly offers to purchase securities. The Company or the selling stockholders may also designate agents from time
to time to solicit offers to purchase securities. Any agent that the Company or the selling stockholders designate, who may be
deemed to be an underwriter as that term is defined in the Securities Act, may then resell such securities to the public at varying
prices to be determined by such agent at the time of resale.
The Company or the selling stockholders
may engage in at the market offerings of the Company's common stock. An at the market offering is an offering of the Company's
common stock at other than a fixed price to or through a market maker. The Company shall name any underwriter that the Company
engages for an at the market offering in a post-effective amendment to the registration statement containing this prospectus. The
Company shall also describe any additional details of the Company's arrangement with such underwriter, including commissions or
fees paid, or discounts offered, by the Company and whether such underwriter is acting as principal or agent, in the related prospectus
supplement.
If the Company or the selling stockholders
use underwriters to sell securities, the Company or the selling stockholders will enter into an underwriting agreement with the
underwriters at the time of the sale to them, which agreement shall be filed as an exhibit to the related prospectus supplement.
Underwriters may also receive commissions from purchasers of the securities. Underwriters may also use dealers to sell securities.
In such an event, the dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
and/or commissions from the purchasers for whom they may act as agents.
Underwriters, dealers, agents and other
persons may be entitled, under agreements that may be entered into with the Company or the selling stockholders , to indemnification
by the Company or the selling stockholders against certain civil liabilities, including liabilities under the Securities Act or
to contribution with respect to payments which they may be required to make in respect of such liabilities. Underwriters and agents
may engage in transactions with, or perform services for, the Company in the ordinary course of business.
If so indicated in the applicable prospectus
supplement, the Company or the selling stockholders may authorize underwriters, dealers or other persons to solicit offers by certain
institutions to purchase the securities offered by the Company or the selling stockholders under this prospectus pursuant to contracts
providing for payment and delivery on a future date or dates. The obligations of any purchaser under these contracts will be subject
only to those conditions described in the applicable prospectus supplement, and the prospectus supplement will set forth the price
to be paid for securities pursuant to those contracts and the commissions payable for solicitation of the contracts.
Any underwriter may engage in over-allotment,
stabilizing and syndicate short covering transactions and penalty bids in accordance with Regulation M of the Exchange Act. Over-allotment
involves sales in excess of the offering size, which create a short position. Stabilizing transactions involve bids to purchase
the underlying security so long as the stabilizing bids do not exceed a specified maximum. Syndicate short covering transactions
involve purchases of securities in the open market after the distribution has been completed in order to cover syndicate short
positions. Penalty bids permit the underwriters to reclaim selling concessions from dealers when the securities originally sold
by such dealers are purchased in covering transactions to cover syndicate short positions. These transactions may cause the price
of the securities sold in an offering to be higher than it would otherwise be. These transactions, if commenced, may be discontinued
by the underwriters at any time.
The Company's common stock is quoted on
The NASDAQ Global Market under the trading symbol "ANIP." The other securities are not listed on any securities exchange
or other stock market and, unless the Company states otherwise in the applicable prospectus supplement, the Company does not intend
to apply for listing of the other securities on any securities exchange or other stock market. Any underwriters to whom the Company
sells securities for public offering and sale may make a market in the securities that they purchase, but the underwriters will
not be obligated to do so and may discontinue any market making at any time without notice. Accordingly, the Company gives you
no assurance as to the development or liquidity of any trading market for the securities.
The anticipated date of delivery of the
securities offered hereby will be set forth in the applicable prospectus supplement relating to each offering.
In order to comply with certain state securities
laws, if applicable, the securities may be sold in such jurisdictions only through registered or licensed brokers or dealers. In
certain states, the securities may not be sold unless the securities have been registered or qualified for sale in such state or
an exemption from regulation or qualification is available and is complied with. Sales of securities must also be made by the Company
or the selling stockholders in compliance with all other applicable state securities laws and regulations.
The Company shall pay all expenses of the
registration of the securities.
EXPERTS
The consolidated balance sheets of ANI
Pharmaceuticals, Inc. and Subsidiary as of December 31, 2013 and 2012, and the related consolidated statements of operations, changes
in stockholders’ equity/(deficit), and cash flows for each of the years in the two-year period ended December 31, 2013, have
been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated
herein by reference, in reliance on the report of such firm given upon their authority as experts in accounting and auditing.
LEGAL MATTERS
If and when the securities being registered
hereunder are issued, the validity of such issuance will be passed upon for the Company by Dentons US LLP, New York, New York.
WHERE YOU CAN FIND
MORE INFORMATION
The Company files annual, quarterly and
periodic reports, proxy statements and other information with the SEC. You may read and copy any materials that the Company files
with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Many of the Company's SEC filings are also
available to the public from the SEC’s Website at "http://www.sec.gov." The Company makes available free of charge
its annual, quarterly and current reports, proxy statements and other information upon request. To request such materials, please
contact Corporate Secretary at the following address or telephone number: ANI Pharmaceuticals, Inc., 210 Main Street West, Baudette,
Minnesota 56623, Attention: Corporate Secretary; (218) 634-3591. Exhibits to the documents will not be sent, unless those exhibits
have specifically been incorporated by reference in this prospectus.
The Company maintains its website at http://www.anipharmaceuticals.com.
The Company's website and the information contained therein or connected thereto are not incorporated into this Registration Statement.
The Company has filed with the SEC a registration
statement on Form S-3 under the Securities Act relating to the securities the Company is offering by this prospectus. This prospectus
does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration
statement. Please refer to the registration statement and its exhibits and schedules for further information with respect to the
Company and the Company's securities. Statements contained in this prospectus as to the contents of any contract or other document
are not necessarily complete and, in each instance, the Company refers you to the copy of that contract or document filed as an
exhibit to the registration statement. You may read and obtain a copy of the registration statement and its exhibits and schedules
from the SEC, as described in the preceding paragraph.
INFORMATION INCORPORATED
BY REFERENCE
The SEC allows the Company to
"incorporate by reference" the information the Company files with them, which means that the Company can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to
be part of this prospectus, and information that the Company files later with the SEC will automatically update and supersede
this information. The Company incorporates by reference the documents filed with SEC listed below:
1. The Company's Annual Report on Form 10-K and Form
10-K/A for the fiscal year ended December 31, 2013, filed with the SEC on February 28, 2014 and March 3, 2014, respectively.
2. The Company's Quarterly Report on Form 10-Q for
the quarter ended March 31, 2014, filed with the SEC on May 12, 2014.
3. The Company's Current Reports on Form 8-K filed
with the SEC on March 5, 2014 (excluding Exhibit 99.1 therein, which is not incorporated by reference herein) and April 4, 2014.
4. The description of the Company's common stock
contained in the Company's Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.,
dated as of July 17, 2013, Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.,
dated as of June 1, 2012, and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc. dated as of October 14, 2009,
filed as Exhibit 3.1 to ANI's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013.
All reports and other documents subsequently
filed by the Company with the SEC pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this prospectus
and before the termination of the offering shall be deemed to be incorporated by reference in this prospectus and to be a part
of this prospectus from the date of filing of such reports and documents. This prospectus also incorporates by reference any documents
that the Company files with the SEC after the date that the initial registration statement is filed with the SEC and before the
effectiveness of the registration statement. Any statement contained in any document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus or in any other subsequently filed document which also is or is deemed to be incorporated by reference
in this prospectus modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as
so modified or superseded, to constitute a part of this prospectus.
$250,000,000
ANI Pharmaceuticals, Inc.
Debt Securities, Preferred Stock and Common
Stock,
Debt Warrants and Equity Warrants
and
3,500,000 Shares of Common Stock Offered
for Resale by Selling Stockholders
No dealer, salesperson or other person
is authorized to provide you with information or to represent anything not contained in this prospectus. You must not rely on any
unauthorized information or representations. The Company and/or Selling Stockholders are offering to sell, and seeking offers to
buy, only the securities of ANI Pharmaceuticals, Inc. covered by this prospectus, and only under circumstances and in jurisdictions
where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time
of delivery of this prospectus or of any sale of the shares.
May 14, 2014
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth all expenses,
other than the underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities
being registered. All of such fees expenses, except for the registration fee, are estimates:
|
|
Amount
(1)
|
|
Securities and Exchange Commission registration fee
|
|
$
|
39,060
|
(2)
|
Accounting fees and expenses
|
|
$
|
5,000
|
|
Legal fees and expenses
|
|
$
|
35,000
|
|
Miscellaneous fees and expenses
|
|
$
|
3,500
|
|
Total
|
|
$
|
82,560
|
|
|
(1)
|
Does not include expenses of preparing any accompanying prospectus supplements, FINRA filing fee, listing fees, transfer
agent fees and other expenses related to future offerings of particular securities.
|
|
(2)
|
Represents the registration fee of $32,200, offset by $6,935 previously paid in connection with unsold securities pursuant
to Rule 415(a)(6) for the primary offering, and $13,795 for the secondary offering.
|
The Company shall bear all expenses in
connection with the issuance and distribution of the securities being offered hereby.
Item 15. Indemnification of Directors and Officers
Article VII of the Company's Restated Certificate
of Incorporation limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law provides that
directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors,
except for liability for (i) any breach of their duty of loyalty to the corporation or its stockholders, (ii) acts or omissions
not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) unlawful payments of dividends or
unlawful stock repurchases or redemptions as provided in Section 174 of the General Corporation Law of the State of Delaware or
(iv) any transaction from which the director derives an improper personal benefit.
Article VI of the Company's Restated Certificate
of Incorporation provides that the Company shall indemnify, to the fullest extent authorized or permitted by law, as the same exists
or may thereafter be amended, any person who was or is made or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of
the Company), by reason of the fact that such person is or was a director or officer of the Company, or is or was serving at the
request of the Company as a director, officer, employee or agent of any other company, partnership, limited liability company,
joint venture, trust, employee benefit plan or other enterprise; provided, however, that the Company shall not indemnify any director
or officer in connection with any action by such director or officer against the Company unless the Company shall have consented
to such action. The Company may, to the extent authorized from time to time by the Company's Board of Directors, provide rights
to indemnification to employees and agents of the Company similar to those conferred in Article VI to directors and officers of
the Company. No amendment or repeal of Article VI shall apply to or have any effect on any right to indemnification provided thereunder
with respect to any acts or omission occurring prior to such amendment or repeal.
Article VIII of the Company's Bylaws provides
that the Company shall indemnify any and all of its directors or officers, including former directors or officers, and any employee,
who serve as an officer or director of any corporation at the request of the Company to the fullest extent permitted under and
in accordance with the laws of the State of Delaware.
The Company has entered into agreements
with all of its directors and officers under which the Company is required to indemnify them against expenses, judgments, penalties,
fines, settlements and other amounts actually and reasonably incurred, including expenses of a derivative action, in connection
with an actual or threatened proceeding if any of them may be made a party because he or she is or was one of the Company’s
directors or officers. The Company will be obligated to pay these amounts only if the director or officer acted in good faith and
in a manner that he or she reasonably believed to be in or not opposed to the best interests of the Company. With respect to any
criminal proceeding, the Company will be obligated to pay these amounts only if the director or officer had no reasonable cause
to believe his or her conduct was unlawful. The indemnification agreements also set forth procedures that will apply in the event
of a claim for indemnification.
These provisions in the Company's Restated
Certificate of Incorporation and Bylaws do not eliminate the officers’ and directors’ fiduciary duty, and in appropriate
circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware
law. In addition, each officer and director will continue to be subject to liability for breach of their duty of loyalty to the
Company for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions
leading to improper personal benefit to the officer or director and for payment of dividends or approval of stock repurchases or
redemptions that are unlawful under Delaware law. The provisions also do not affect an officer’s or director’s responsibilities
under any other law, such as the federal securities laws or state or federal environmental laws.
Item 16. Exhibits
Exhibit No.
|
|
Description
|
|
Method of Filing
|
|
|
|
|
|
3.1
|
|
Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of July 17, 2013, Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of June 1, 2012, and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.
|
|
Incorporated by reference to Exhibit 3.1 to ANI's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (File No. 001-31812)
|
|
|
|
|
|
3.2
|
|
Amended and Restated Bylaws of BioSante Pharmaceuticals, Inc.
|
|
Incorporated by reference to Exhibit 3.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 11, 2010 (File No. 001-31812)
|
|
|
|
|
|
4.1
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of August 13, 2009
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on August 14, 2009 (File No. 001-31812)
|
|
|
|
|
|
4.2
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of September 2010
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 5, 2010 (File No. 001-31812)
|
|
|
|
|
|
4.3
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of June 2010
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 21, 2010 (File No. 001-31812)
|
|
|
|
|
|
4.4
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of December 2010
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on December 29, 2010 (File No. 001-31812)
|
|
|
|
|
|
4.5
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of March 2011
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 4, 2011 (File No. 001-31812)
|
4.6
|
|
Form of Common Stock Purchase Warrant issued by BioSante Pharmaceuticals, Inc. with an Initial Exercise Date of August 2012
|
|
Incorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K as filed with the Securities and Exchange Commission on August 17, 2012 (File No. 001-31812)
|
|
|
|
|
|
4.7
|
|
Form of Senior Indenture between ANI and The Bank of New York Mellon, as trustee
|
|
Filed herewith
|
|
|
|
|
|
4.8
|
|
Form of Subordinated Indenture between ANI and The Bank of New York Mellon, as trustee
|
|
Filed herewith
|
|
|
|
|
|
4.9
|
|
Form of Senior Debt Security
|
|
To be filed, if necessary, by a Current Report on Form 8-K or by amendment
|
|
|
|
|
|
4.10
|
|
Form of Subordinated Debt Security
|
|
To be filed, if necessary, by a Current Report on Form 8-K or by amendment
|
|
|
|
|
|
4.11
|
|
Form of Certificate of Designations of Preferred Stock
|
|
To be filed, if necessary, by a Current Report on Form 8-K or by amendment
|
|
|
|
|
|
4.12
|
|
Form of Warrant Agreement, including Form of Warrant Certificate
|
|
To be filed, if necessary, by a Current Report on Form 8-K or by amendment
|
|
|
|
|
|
5.1
|
|
Opinion of Dentons US LLP, legal counsel
|
|
Filed herewith
|
|
|
|
|
|
23.1
|
|
Consent of EisnerAmper LLP, independent registered public accounting firm
|
|
Filed herewith
|
|
|
|
|
|
23.2
|
|
Consent of Dentons US LLP, legal counsel
|
|
Filed herewith (included in the opinion filed as Exhibit 5.1)
|
|
|
|
|
|
24.1
|
|
Powers of Attorney
|
|
Filed herewith (included in signature page to this registration statement)
|
|
|
|
|
|
25.1
|
|
Form T-1 Statement of Eligibility of Trustee for the Senior Indenture under the Trust Indenture Act of 1939
|
|
Filed herewith
|
|
|
|
|
|
25.2
|
|
Form T-1 Statement of Eligibility of Trustee for the subordinated Indenture under the Trust Indenture Act of 1939
|
|
Filed herewith
|
Item 17. Undertakings
(a) The undersigned registrant hereby undertakes:
(1) To file, during any
period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus
required by section 10(a)(3) of the Securities Act;
(ii) To reflect in the
prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective registration statement;
(iii) To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;
provided
,
however
,
that
(A) paragraphs (1)(i) and
(1)(ii) do not apply if the registration statement is on Form S-8 and the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section
13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
(B) paragraphs (1)(i), (1)(ii)
and (1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3, and the information required
to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission
by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2) That, for the purpose
of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
(3) To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose
of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities,
in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
(i) Any preliminary prospectus
or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus
relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
(iii) The portion of any
other free writing prospectus relating to the offering containing material information about the undersigned registrant or its
securities provided by or on behalf of the undersigned registrant; and
(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.
(b) The undersigned registrant hereby undertakes
that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant
to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual
report pursuant to section 15(d) of the Exchange) that is incorporated by reference in the registration statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(c) The undersigned registrant hereby undertakes
to supplement the prospectus, after the expiration of the subscription period, to set forth the results of the subscription offer,
the transactions by the underwriters during the subscription period, the amount of unsubscribed securities to be purchased by the
underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters is to be made on terms
differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to set forth the terms
of such offering.
(d) Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
(e) The undersigned registrant hereby undertakes
that:
(1) For purposes of determining
any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or
(4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective.
(2) For the purpose of
determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(f) The undersigned registrant hereby undertakes
to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of section 310
of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under section 305(b)(2) of
the Act.
SIGNATURES
Pursuant to the requirement of the Securities
Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in
the City of Wilmington, State of Delaware, on the 14th day of May, 2014.
|
ANI PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Charlotte C. Arnold
|
|
|
Charlotte C. Arnold
Vice President, Finance and Chief Financial Officer
|
We, the undersigned officers and directors
of ANI Pharmaceuticals, Inc., and each of us, do hereby constitute and appoint each of Arthur S. Przybyl and Charlotte C. Arnold,
or any of them, each acting alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution,
to do any and all acts and things in our name, place and stead, in any and all capacities, in connection with this registration
statement on Form S-3 under the Securities, or any registration statement for the same offering that is to be effective upon filing
under the Securities Act, including, without limitation, to sign for us or any of us in our names in the capacities indicated below
any and all amendments or supplements to this registration statement, including any and all stickers and post-effective amendments
to the registration statement, and to sign any and all additional registration statements relating to the same offering of securities
as this registration statement that are filed pursuant to Rule 462(b) under the Securities Act, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities
exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, each acting alone, full power and
authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully
to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or their substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
|
|
Name & Title
|
|
Date
|
|
|
|
|
|
/s/ Arthur S. Przybyl
|
|
Arthur S. Przybyl
|
|
May 14, 2014
|
|
|
President, Chief Executive Officer and Director
|
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Charlotte C. Arnold
|
|
Charlotte C. Arnold
|
|
May 14, 2014
|
|
|
Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Robert E. Brown, Jr.
|
|
Robert E. Brown, Jr.
|
|
May 14, 2014
|
|
|
Chairman of the Board of Directors
|
|
|
|
|
|
|
|
/s/ Fred Holubow
|
|
Fred Holubow
|
|
May 14, 2014
|
|
|
Director
|
|
|
|
|
|
|
|
/s/ Ross Mangano
|
|
Ross Mangano
|
|
May 14, 2014
|
|
|
Director
|
|
|
|
|
|
|
|
/s/ Tracy L. Marshbanks, Ph.D.
|
|
Tracy L. Marshbanks, Ph.D.
|
|
May 14, 2014
|
|
|
Director
|
|
|
|
|
|
|
|
/s/ Thomas A. Penn
|
|
Thomas A. Penn
|
|
May 14, 2014
|
|
|
Director
|
|
|
|
|
|
|
|
/s/ Daniel Raynor
|
|
Daniel Raynor
|
|
May 14, 2014
|
|
|
Director
|
|
|
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2023 to Apr 2024